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“Kyllä te vietätte elämää! Korjaatte, puuhaatte ja hypitte aamusta iltaan. Mokoma 
hosuminen voi olla vaarallista. Johan sitä masentuu kun vain ajatteleekin kaikkia 
niitä, jotka tekevät työtä ja raatavat, ja mitä hyötyä siitä muka on. Eräs sukulaiseni 
luki trigonometriaa tuntokarvansa lerpalleen, ja kun hän oli oppinut kaiken, tuli 
Mörkö ja söi hänet suuhunsa. Joopa joo, Mörön vatsassa hän sitten lojui niin 
erinomaisen viisaana!”
Tove Jansson, Muumipapan villi nuoruus, 1950 
”What a life! No end of changing and building up and pulling down again and 
jumping about. Such a lot of work may turn out to be really harmful. Oh, I’m 
dejected just to think of all the people who work and buzz and bumble about, and 
what it leads to. I had a cousin once who studied trigonometry until his whiskers 
drooped, and when he had learnt it all a Groke came and ate him up. Yes, so wise he 
was while lying in the Groke’s stomach!” 
Tove Jansson, The Exploits of Moominpappa, Described by Himself, 1950 
To my family 
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ABSTRACT
Autism (MIM 209850) is a severe neurodevelopmental disorder characterized by 
abnormalities in reciprocal social interaction and communication, restricted and 
stereotyped patterns of interests and activities, and the presence of developmental 
abnormalities, which are evident by the age of three years. Autism is the most severe 
form of a broad group of disorders known as pervasive developmental disorders (PDD) 
or autism spectrum disorders (ASD), which include also milder conditions such as 
Asperger syndrome (AS), disintegrative disorder, and atypical forms of autism. The 
population prevalence for autism is 10-20 per 10 000, whereas the total prevalence for 
all autism spectrum disorders is close to 10-60 per 10 000. Twin and family studies have 
repeatedly and unequivocally indicated a strong genetic component in ASDs, but the 
underlying genetic mechanisms are still largely unknown.  
To analyze the genetic factors underlying autism, we have carried out two genome-wide 
scans in well characterized Finnish ASD families. First, we analyzed 38 families having 
diagnoses of autism, AS and developmental dysphasia, and identified a susceptibility 
locus at 3q25-27 with a maximum multipoint LOD score of 4.81. Also, other putative 
linkage findings were observed at 1q21-23 and Xq13. The second genome-wide scan 
was performed in a sample of 17 extended families with AS. The most solid linkage 
finding was observed at 3p14-24 with the highest multipoint NPLall score of 3.32. Other 
suggestive findings were identified at 1q21-23 and 13q31-33. Next, we analyzed the data 
from genome-wide scans performed in the US and Finnish autism samples combined, in 
order to reveal shared susceptibility loci for these two samples. The most promising 
shared locus was identified at 3p24-26 (NPLall=2.20) in the vicinity of the earlier finding 
in the AS-sample.  
Two members of the neuroligin gene family, NLGN3 and NLGN4, have been shown to 
be mutated in individuals with autism, AS and mental retardation. Two neuroligin genes, 
NLGN1 at 3q26 and NLGN3 at Xq13, are located within the putative susceptibility loci 
identified in the first genome scan of this study. However, no evidence for functional 
mutations or significant allelic association was observed at NLGN1, NLGN3 or NLGN4
in the Finnish sample.  
Recently, DYX1C1 was identified as a candidate for developmental dyslexia in a Finnish 
study sample. It has been suggested that variants at this gene might confer susceptibility 
also for other disorders involving language development or acquiring specific 
competences. Therefore, we wanted to test whether the effect is present also in autism, 
which is an extreme example of such a disorder. No evidence for association or deviated 
allelic diversity in the haplotype analyses was observed, and thus, at least a presence of a 
major effect was excluded.  
Taken together, the present study has involved the identification of potential 
susceptibility loci for ASDs at 1q21-23, 3p14-26, 3q25-27, 13q31-33, and Xq13. As the 
initial follow-up of the genome-wide scans, the most relevant candidates were analyzed 
but with no indication of etiological significance. The original articles included in this 
thesis represent the first step towards identification of susceptibility genes for ASDs in 
the Finnish population and this data provides a strong foundation for future fine-scale 
mapping of the identified loci. 
Keywords: autism, Asperger syndrome, genetic mapping, linkage analysis, association 
analysis, neuroligin, oxytocin receptor, dyslexia, dysfasia 
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TIIVISTELMÄ
Autismikirjon sairaudet (MIM 209850) ovat vakavia lapsuusiällä alkavia sairauksia, 
joille on ominaista vastavuoroisen kommunikaation häiriöt, kielen kehityksen ongelmat, 
ja stereotyyppiset sekä toistuvat käyttäytymismallit. Autismikirjon sairauksiin kuuluvat 
lapsuusiän autismi, Aspergerin oireyhtymä ja epätyypilliset autismin muodot. Autismin 
yleisyys väestössä on 10-20 / 10 000, kun taas autismikirjon sairauksien 
kokonaisesiintyvyys on 10-60 / 10 000. Kaksos- ja perhetutkimukset ovat toistuvasti 
osoittaneet että autismikirjon sairaudet ovat vahvasti geneettisiä. Tästä huolimatta 
autismille altistavat geneettiset mekanismit ovat vielä epäselviä. 
Tutkimuksen tarkoituksena oli paikantaa autismille altistavia geneettisiä tekijöitä 
genominlaajuisten kartoitustutkimusten avulla. Ensimmäisessä osatyössä analysoimme 
38 hyvin kuvattua suomalaista perhettä, joissa esiintyi autismia, Aspergerin oireyhtymää 
ja kielenkehityksen viivettä (dysfasia). Lupaavin alttiusgeenialue löytyi kromosomista 
3q25-27 (MLS=4.81). Muita mahdollisia alttiusgeenialueita paikansimme 
kromosomeista 1q21-23 sekä Xq13. Seuraavaksi suoritimme genominlaajuisen 
kartoituksen 17 laajassa suomalaisessa perheessä, jossa esiintyy Aspergerin oireyhtymää 
ainoana autismikirjon sairautena. Lupaavin kytkentälöydös oli kromosomissa 3p14-24 
(NPLall = 3.32) ja muita mahdollisia alttiusgeenialueita paikansimme kromosomeista 
1q21-23 sekä 13q31-33. Kolmannessa osatyössä analysoimme työn I geneettisen 
informaation yhdessä yhdysvaltalaisen Autism Genetic Resource Exchange (AGRE) – 
aineiston kanssa tarkoituksena etsiä näille aineistoille yhteisiä alttiusgeenialueita. 
Lupaavin yhteinen alttiusgeenialue löytyi kromosomista 3p24-26 (NPLall = 3.32). Tämä 
alttiusgeenialue on lähellä toisessa osatyössä paikannettua lupaavaa Asperger-lokusta.  
Neuroligin-geeniperheeseen kuuluu viisi keskenään hyvin samankaltaista jäsentä, joista 
kahden (3 ja 4) on vastikään osoitettu mutatoituneen harvinaisissa tapauksissa autistisilla 
ja kehitysvammaisilla potilailla. Neuroligin-geeneistä kaksi, NLGN1 kromosomissa 3q26 
ja NLGN3 kromosomissa Xq13, sijaitsevat ensimmäisessä osatyössä paikannetuilla alt-
tiusgeenialueilla. NLGN1, NLGN3 tai NLGN4 geenien toimintaan vaikuttavia mutaatioi-
ta tai alleeliassosiaatiota näillä alueilla ei kuitenkaan havaittu suomalaisissa autismiper-
heissä.
Suomalaisessa aineistossa on paikannettu lukihäiriölle mahdollisesti altistavia muutoksia 
kromosomissa 15 sijaitsevassa DYX1C1-geenissä. Kirjallisuudessa on esitetty, että tä-
män geenin muutokset saattavat altistaa myös laajemmalle kirjolle kehityksellisiä häiri-
öitä, etenkin kielenkehitykseen liittyen. Tutkimme tämän geenin alleeliassosiaatiota au-
tismiaineistossamme, mutta emme löytäneet näyttöä DYX1C1-geenin osuudesta autismin 
syntyyn. 
Tässä tutkimuksessa paikansimme mahdollisia autismikirjon sairauksien alttiusgeenialu-
eita kromosomeista 1q21-23, 3p14-26, 3q25-27, 13q31-33 ja Xq13. Alustavana jatkotut-
kimuksena analysoimme selkeitä alttiusgeenikandidaatteja näiltä alueilta, mutta emme 
havainneet näyttöä näiden geenien osuudesta autismin syntyyn. Tässä tutkimuksessa 
esitetyt osatyöt ovat ensimmäinen askel kohti autismin alttiusgeenien paikantamista 
suomalaisessa väestössä ja ne luovat vahvan perustan kyseisten alueiden tihennyskartoi-
tustutkimuksille.  
Avainsanat: autismi, Aspergerin oireyhtymä, geenikartoitus, kytkentäanalyysi, assosiaa-
tioanalyysi, neuroligin, oksitosiinireseptori, lukihäiriö, dysfasia 
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1. INTRODUCTION 
The genetic mapping approach offers tools for the identification of the genetic 
architecture of a disease, and thus, for understanding the biological mechanisms 
underlying the disease phenotype. Positional cloning has successfully been applied to 
detect causative variants for rare Mendelian disorders, which result from mutations of 
large functional effect. Inspired by this success, huge efforts are now directed to the 
genetic mapping of common phenotypes, such as asthma and allergy, cancer, 
cardiovascular disorders and mental disorders, which constitute a significant proportion 
of the public health burden. Common diseases are caused by a varying number of 
genetic, cultural, and environmental risk factors, each contributing a minor effect and 
probably having multiple interactions with each other. Identification of genetic variants 
for such phenotypes has turned out to be more difficult than initially thought, and it is 
now evident that revealing the genetic basis of these diseases requires substantial efforts 
in terms of sample collection and phenotyping as well as technological and statistical 
development.  
Autism spectrum disorders, characterized by impairments in communication and social 
interaction as well as the presence of repetitive and restricted activities, are among the 
most strongly genetic neuropsychiatric disorders. Many rare causative genetic factors are 
known for autism, including chromosomal abnormalities, fragile X syndrome, and 
mutations in neuroligin genes. It is clear that functional characterisation of these 
pathways will provide novel information about the pathophysiology underlying autism. 
However, more prevalent causes are still unknown. Several genomewide linkage scans 
have been performed in order to reveal those chromosomal loci that might contain 
variants predisposing to autism spectrum disorders. These studies have resulted in some 
overlapping findings but, as in most other complex disorders, poor reproducibility has 
been the predominant result. Similarly, most of the candidate gene studies have resulted 
in conflicting results. However, this is expected given that the genetic background is 
likely to be a mixture of rare single-gene mutations and common variants contributing a 
16
minor effect. It is therefore likely that most of the previous efforts have been 
underpowered to detect the predisposing genetic effects. Novel technological, statistical, 
and study design issues have been proposed to overcome these problems, as will be 
discussed in the following chapters.
17
2. REVIEW OF THE LITERATURE 
2.1 Autism Spectrum Disorders 
2.1.1 Historical background 
In 1943, Leo Kanner described 11 children, who had significant impairments in 
reciprocal social interactions and communication skills. Other clinical features included 
delayed early language development as well as repetitive and ritualistic interests and 
activities. This condition was named “infantile autism” (Kanner 1943). Asperger 
syndrome was first described in 1944 by Hans Asperger, who reported a group of boys 
with “autistic psychopathy”. The clinical features of these boys included difficulties in 
social interaction and communication as well as circumscribed and restricted patterns of 
interest (Asperger 1944; Asperger 1991). Asperger was unaware of the previous work by 
Kanner (1943), in which these features were also included. The main differences 
between these early reports were that the patients described by Asperger were of higher 
intelligence, and the apparent onset of the condition seemed to be somewhat later than in 
autism. Furthermore, language skills were acquired on time in Asperger’s patients and 
the motor deficits were more common. After the English review by Wing (Wing 1981), 
the combination of problems described by Asperger is generally referred to as Asperger 
syndrome (AS). It is worth noting that highly similar cases to those described by 
Asperger had been described already in 1926 by Eva Ssucharewa (translated in 
Ssucharewa and Wolff 1996). The patients in this early report were said to have a 
“schizoid personality disorder” and they were practically indistinguishable to those 
described later by Hans Asperger.  
Nowadays, infantile autism is considered to be the prototype of disorders in a group 
called pervasive developmental disorders (PDD), which also include Asperger 
syndrome, childhood disintegrative disorder, Rett syndrome and pervasive 
developmental disorder-not otherwise specified (PDD-NOS) (World Health 
Organization 1993; American Psychiatric Association 1994). Autism, AS and PDD-NOS 
are also commonly referred to as autism spectrum disorders (ASD). While the criteria for 
18
autism have been relatively well established for a long time, several alternative 
diagnostic concepts have been used to diagnose AS (Wing 1981; Tantam 1988; Gillberg 
and Gillberg 1989; Szatmari et al. 1989; World Health Organization 1993; American 
Psychiatric Association 1994). Therefore, the research findings concerning AS are 
sometimes difficult to interpret.  
2.1.2 Diagnostic criteria and co-existing phenotypes 
The diagnoses of autism and AS are currently outlined in the International Classification 
of Diseases (ICD-10; World Health Organization 1993) and in the 4th edition of 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric 
Association 1994). The diagnosis of autism is based on three core symptoms, which 
include (i) qualitative impairment in reciprocal social interaction, (ii) qualitative 
impairment in verbal and non-verbal communication and imaginative activity, and (iii) a 
markedly restricted repertoire of interests and activities (Table 1). These symptoms are 
present before the age of 3 years. The criteria for AS are the same as those for autism 
with three main exceptions: (i) the communication and imagination impairment criteria 
for autism are not listed for AS, (ii) individuals with AS do not have a clinically 
significant general delay in language and (iii) individuals with AS do not have a 
clinically significant delay in cognitive development (Table 2)(Nieminen-Von Wendt 
2004). Furthermore, unlike autism, AS is usually recognized after the age of 3 years, or 
the problems in communication and social interactions before that age must not be of the 
type seen in autism (Volkmar and Klin 2000). 
Numerous overlapping conditions commonly exist in patients with autism or AS. Some 
75-80% of individuals with autism have mental retardation (MR) and 20-30% have 
epilepsy (Bailey et al. 1996; Gillberg & Billstedt 2000). Both autism and AS are 
commonly associated with sleeping problems (Gillberg and Billstedt 2000; Tani et al. 
2003) and altered sensibility (Gillberg and Billstedt 2000; Nieminen-Von Wendt 2004). 
Motor clumsiness and prosopagnosia (face recognition difficulties) are commonly 
19
observed in individuals with AS (Gillberg and Billstedt 2000; Smith 2000; Nieminen-
Von Wendt 2004). In addition, several neuropsyciatric disorders, including attention 
deficit hyperactivity disorder (ADHD), tics and Tourette syndrome, depression, eating 
disorders, obsessive-compulsive behaviour, and schizophrenia spectrum disorders, may 
co-exist with the ASDs, especially with AS (Gillberg et al. 1996; Ghaziuddin et al. 1998; 
Gillberg and Billstedt 2000; Ringman and Jankovic 2000; Wolff 2000; Nieminen-Von 
Wendt 2004; Nieminen-von Wendt et al. 2005). 
20
Table 1. Diagnostic criteria for autism according to the ICD-10 classification 
(World Health Organization 1993).
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
A. Presence of abnormal or impaired development before the age of three years, in at least one 
out of the following areas: 
1. receptive or expressive language as used in social communication 
2. the development of selective social attachments or of reciprocal social interaction 
3. functional or symbolic play 
B. Qualitative abnormalities in reciprocal social interaction, manifest in at least one of the 
following areas: 
1. failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture to 
regulate social interaction. 
2. failure to develop (in a manner appropriate to mental age, and despite ample opportunities) 
peer relationships that involve mutual sharing of interests, activities and emotions. 
3. A lack of socio-emotional reciprocity as shown by an impaired or deviant response to other 
people’s emotions; or lack of modulation of behaviour according to social context, or a weak 
integration of social, emotional and communicative behaviours. 
C. Qualitative abnormalities on communication, manifest in at least two of the following areas: 
1. a delay in, or total lack of development of spoken language that is not accompanied by an 
attempt to compensate through the use of gesture or mime as alternative modes of 
communication (often preceded by a lack of communicative babbling) 
2. relative failure to initiate or sustain conversational interchange (at whatever level of language 
skills are present) in which there is reciprocal to and from responsiveness to communications 
of the other person 
3. Stereotyped and repetitive language or idiosyncratic use of words or phrases 
4. abnormalities in pitch, stress, rate, rhythm and intonation of speech 
D. Restricted repetitive, and stereotyped patterns of behaviour, interests and activities, manifest 
in at least two of the following areas: 
1. an encompassing preoccupation with one or more stereotyped and restricted patterns of 
interest that are abnormal in content or focus; or one or more interests that are abnormal in 
their intensity and circumscribed nature although not abnormal in their content or focus. 
2. apparently compulsive adherence to specific, non-functional, routines or rituals 
3. stereotyped and repetitive motor mannerisms that involve either hand or finger flapping or 
twisting, or complex whole body movements 
4. preoccupations with part-objects or non-functional elements of play materials (such as their 
odour, the feel of their surface, or the noise or vibration that they generate) 
5. distress over changes in small non-functional, details of environment 
E. The clinical picture is not attributable to other varieties of pervasive developmental disorder; 
specific developmental disorder of receptive language (F80.2) with secondary socio-emotional 
problems; reactive attachment disorder (F94.1) or disinhibited attachment disorder (F94.2); 
mental retardation (F70-72) with some associated emotional or behavioural disorder; 
schizophrenia (F20) of unusually early onset; and Rett’s syndrome (F84.2). 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
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Table 2. Diagnostic criteria for Asperger syndrome according to the ICD-10 classi-
fication (World Health Organization 1993).
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
A. A lack of any clinically significant general delay in spoken or receptive language or cognitive 
development. Diagnosis requires that single words should have developed by 2 years of age or 
earlier and that communicative phrases be used by 3 years of age or earlier. Self-help skills, 
adaptive behaviour, and curiosity about the environment during the first 3 years should be at 
a level consistent with normal intellectual development. However, motor milestones may be 
somewhat delayed and motor clumsiness is usual (although not a necessary diagnostic fea-
ture). Isolated special skills, often related to abnormal preoccupations, are common, but are 
not required for the diagnosis. 
B. Qualitative abnormalities in reciprocal social interaction (criteria as for autism). Diagnosis 
requires demonstrable abnormalities in at least two out of the following four areas: 
1. Failure adequately to use eye-to-eye gaze, facial expression, body posture and gesture to regu-
late social interaction. 
2. Failure to develop (in a manner appropriate to mental age, and despite ample opportunities) 
peer relationships that involve a mutual sharing of interests, activities and emotions. 
3. Lack of socio-emotional reciprocity as shown by an impaired or deviant response to other 
people’s emotions, and/or lack of modulation of behaviour according to social context, and/or 
a weak integration of social, emotional and communicative behaviours 
4. Lack of spontaneous seeking to share enjoyment, interests or achievements with people (e.g. a 
lack of showing, bringing or pointing out to other people objects of interests to the individual) 
C. An unusually intense circumscribed interests, or restricted, repetitive, and stereotyped pat-
terns of behaviour, interests, and activities (criteria as for autism, however it would be less 
usual for these to include either motor mannerisms or preoccupations with part-objects or 
non-functional elements of play materials). Diagnosis requires demonstrable abnormalities in 
at least two out of the following four areas: 
1. An encompassing preoccupation with one or more stereotyped and restricted patterns of inter-
ests that is abnormal in context or focus; or one or more interests that are abnormal in their in-
tensity and circumscribed nature though not in their content or focus. 
2. Apparently compulsive adherence to specific, non-functional routines or rituals. 
3. Stereotyped and repetitive motor mannerisms that involve either hand/finger flapping or twist-
ing, or complex whole body movements. 
4. Preoccupation with part-objects or non-functional elements of play materials. 
D. The disorder is not attributable to other varieties of pervasive developmental disorder; schizo-
typal disorder (F21); simple schizophrenia (F20.6); reactive and disinhibited attachment dis-
orders of childhood (F94.1 and .2); obsessional personality disorder (F60.5); obsessive-
compulsive disorder (F42). 
⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯
2.1.3 Prevalence of Autism Spectrum Disorders 
The prevalence for ASDs has traditionally been reported as 4-6 / 10 000 for strictly 
defined autism and 20 / 10 000 for the broad spectrum of ASDs (Charman 2002). It 
seems likely, however, that the current true prevalence for ASDs is considerably higher 
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than previously thought. For example, Chakrabarti and Fombonne (2001) reported a 
prevalence of 16.8 / 10 000 (95% CI, 11.0-24.6) for autism and a total prevalence of 
62.6 / 10 000 (95% CI, 50.8-76.3) for all PDDs in an English study population of 15 500 
children. An US study by Yeargin-Allsopp et al. (2003) reported a prevalence of 34 / 10 
000 (95% CI, 32-36) for ASDs in a study population of 289 456 children in the Atlanta 
metropolitan area. Also, other recent epidemiological studies for ASDs, including one 
conducted in the Northern Finnish population (Kielinen et al. 2000), have yielded similar 
prevalence estimates (Charman 2002). The apparent increase in prevalence most 
probably arise from the increased recognition of ASDs, the broadening of the diagnostic 
concept over time, and methodological differences, e.g. novel screening methodology, 
which may powerfully affect the prevalence estimates. An alternative, but far more 
unlikely, explanation for the increased prevalence of ASDs is the recent emergence of 
some powerful but yet unidentified environmental factors (Chakrabarti and Fombonne 
2001; Charman 2002; Yeargin-Allsopp et al. 2003). A highly consistent finding in the 
epidemiological studies is that there is a clear excess of males in both autism and AS 
with the male-female ratio being around three to one (Ehlers and Gillberg 1993; 
Chakrabarti and Fombonne 2001; Charman 2002; Yeargin-Allsopp et al. 2003). 
So far, only one study has been conducted, in which the prevalence of AS has been 
investigated exclusively without taking other ASDs into account. A prevalence rate of 
28.5 / 10 000 (95% CI, 0.6-56.5) was reported with ICD-10 criteria in a small study 
population of 1519 Swedish children. A slightly higher prevalence estimate of 36 / 10 
000 was obtained when the criteria of Gillberg and Gillberg (1989) were used (Ehlers 
and Gillberg 1993). The prevalence estimates for AS in those studies that have focused 
on ASDs in general have ranged significantly from 0.3 to 48.4 / 10 000, indicating major 
diagnostic and methodological differences across the studies. Many of these studies 
have, for example, focused on such young age groups, that AS is usually not recognized. 
In addition, the diagnosis of AS is not well established in many countries potentially 
leading to too low prevalence estimates. It has been suggested that a conservative 
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estimate might be around 2 / 10 000, but it is probably fair to conclude that there are 
currently no reliable prevalence estimates for AS (Fombonne and Tidmarsh 2003). 
2.2 Genetic mapping of complex diseases 
Genetic mapping studies aim to detect correlation between the genotypes of marker loci 
and the phenotype of interest and to identify those genomic regions, which include the 
genetic variant(s) influencing the trait of interest. Ultimately, the goal is to be able to 
identify the specific predisposing genetic variant(s) among the ~3x109 nucleotides in the 
human genome. Conventional genetic mapping studies start by collecting family 
material of a sufficient size for linkage analysis. For this purpose, DNA from families 
with two or more affected individuals is needed. These samples are analysed in a 
genome-wide scan, which employs a genome-wide set of polymorphic genetic markers 
covering the entire human genome usually at 4-10 centiMorgan (cM) intervals (400-
1000 genetic markers). Genetic mapping utilises a phenomenon called linkage, which 
means the tendency of two closely spaced loci in the genome to be inherited together 
rather than independently. In linkage analysis, the chromosomal localisation of a disease 
gene is statistically determined by comparing the inheritance of marker alleles with the 
inheritance of the disease within families. The obvious advantage of this approach is that 
it is based solely on the knowledge that the phenotype is inherited and no prior 
knowledge is needed about the disease pathogenesis. Therefore, identification of disease 
mutations is usually the primary route towards understanding the biological mechanisms 
underlying the disease phenotype (Botstein and Risch 2003). 
Once a disease gene has been assigned to a certain chromosomal locus, fine-scale 
mapping by analysing more families and a denser set of genetic markers is usually 
performed. The region harbouring the disease-causing gene can be restricted by 
recombinations within the families (linkage) or, in the presence of linkage disequilibrium 
(LD), by the ancient recombinations (see, 2.2.6). In some cases, chromosomal 
abnormalities may provide a shortcut for disease gene identification (2.3.3). As a result 
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of the Human Genome Project (HGP) and the competitive genome project by Celera 
Genomics, the identification of human disease genes has changed dramatically (Lander 
et al. 2001; Venter et al. 2001). Bioinformatic approaches rather than laborious 
positional cloning process can be directly used to identify known genes, expressed-
sequence tags (EST), or predicted genes from the region of interest. In addition, the 
availability of the complete sequences of several organisms enables comparative 
genomic approaches to identify new genes, regulatory elements, or other functionally 
important regions of the genome (Miller et al. 2004). The positional candidates are 
analysed in the patient samples in order to identify the disease-causing variant. Several 
methods are used to test the validity of identified variants as disease-causing mutations. 
These include e.g. testing association with the phenotype, comparative genomic 
approaches, in silico modelling of the protein structure and function, functional analyses 
in vitro and, ultimately, functional analyses in model organisms (Figure 1). 
The most success in genetic mapping has been experienced in simple and rare Mendelian 
diseases (Botstein and Risch 2003). Mendelian diseases have clearly identifiable 
inheritance patterns, meaning that the disease must result from a single mutation of a 
large functional effect. By contrast, the success in the identification of genetic variants 
responsible for common complex phenotypes has not been impressive so far (Altmuller 
et al. 2001). Complex traits are much less clear in their inheritance patterns because 
these phenotypes result from the combined effects of many genetic variants, 
environmental factors and cultural factors (Risch 2000; Weiss and Terwilliger 2000; 
Glatt and Freimer 2002). Most problems encountered in disease mapping of complex 
diseases are caused by a lack of one-to-one correlation between genotype and the 
diagnostic disease phenotype (Figure 2). At present, several of the mapped complex 
disease genes account for an uncommon subset of generally more common disorders 
(Risch 2000).  
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Figure 1. Genetic mapping – an overview. The gene mapping effort starts with a 
genomewide scan (1-2) and the positive regions are followed up by using more samples 
and a denser map of markers (3).  Positional candidates are identified from the databases 
(4) and the genetic variants potentially conferring susceptibility are identified by SNP 
association and mutation analyses (5). The validity of identified variants is tested in large 
population samples and by functional analyses (6). 
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Figure 2. A simplified model of the etiological factors predisposing to complex 
diseases.  In genetic mapping studies, the correlation between marker locus genotype 
and disease phenotype (1) is tested. Therefore, its success depends on both a correlation 
between the marker locus and the disease gene (linkage, 2) and also on a correlation 
between the disease gene and the phenotype (3). In Mendelian disorders, the correlation 
between the trait phenotype and disease gene (3) is strong, and the success depends 
primarily on how closely the tested marker is correlated with the disease gene. The 
existence of other predisposing factors, such as other susceptibility genes (4) and 
environmental and cultural factors (5), reduce the correlation between the disease gene 
and the phenotype (3) and, thus, the tested correlation (1). This is the situation usually 
observed in complex phenotypes. Modified from Weiss and Terwilliger (2000). 
2.2.1 Determining the genetic component in complex disorders 
Many common disorders are caused by a varying number of susceptibility genes, 
environmental factors, or both combined. Only individuals, whose liability exceeds a 
certain threshold, manifest the disease (Figure 3). Because the affected individuals’ 
relatives have a higher risk for predisposing factors than the general population, they 
also have, on average, a higher liability for the disease (Farrer and Cupples 1998).  
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Figure 3. The multifactorial threshold model. The predisposing factors for the disease 
are normally distributed in the population. The individuals whose liability exceeds the 
threshold manifest the disease. The sibs of affected individuals have a higher average 
liability than the population mean and a greater proportion of them have liabilities 
exceeding the threshold (modified from Strachan and Read 2004).  
The determination of a genetic component is a crucial step preceding genetic mapping 
studies because their success is highly dependent on the correlation between a genotype 
and a disease phenotype (Figure 2).  The first step towards identification of the genetic 
component is the determination of familial aggregation. When a disease has genetic 
aetiology, the affected probands’ first-degree relatives have an increased risk for the 
disease compared with the risk in more distant relatives or in the general population. 
Therefore, the degree of familial clustering can be measured as a familial recurrence 
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risk, λr, which is the ratio of the risk for the affected probands’ relatives versus the 
disease prevalence in population (λr=kr/k, where λr is familial recurrence risk, kr is the 
risk of the affected proband’s relatives, and k is the prevalence in general population;
Risch 1990). The most frequently used familial recurrence risk is sibling risk, λs, which 
is the recurrence risk in the probands’ siblings versus the risk in the general population. 
Familial aggregation of a trait is not a sufficient proof for genetic aetiology and more 
sophisticated methods have been developed to prove a genetic basis. Twin and adoption 
studies have been specially suited for diseases, where making a distinction between 
genetic and environmental factors is difficult. A classical twin study compares the 
concordance of monozygotic (MZ) and dizygotic (DZ) twins for a trait indicating the 
relative importance of genetic and environmental effects. The difference between MZ 
and DZ concordance indicates a strong genetic effect whereas equal concordance 
between MZ and DZ twins or low MZ concordance suggest strong environmental effects 
(Allen et al. 1967). Twin studies can be used to determine another important measure, 
heritability (h2), which is defined as the proportion of the total variance of the phenotype 
that is genetic (h2=VG/VP, where VG is genetic variance and VP is overall variance of the 
phenotype) (Strachan and Read 2004). If rMZ is a correlation in MZ twins and rDZ is a 
correlation in DZ twins, the heritability can be defined as h2=2(rMZ-rDZ) (Boomsma et al. 
2002). 
Segregation analyses are used for determining whether a major genetic component is 
involved in the aetiology of a trait. A variety of both genetic and non-genetic models are 
tested, and the best model fitting the family data is estimated by likelihood ratio tests 
(Farrer and Cupples 1998; Strachan and Read 2004).  
2.2.2 Genetic markers and maps 
Currently, the most common markers for genome scanning purposes are microsatellites 
(short tandem repeats, STR), which are di-, tri-, or tetranucleotide repeats flanked by 
29
unique sequences on both sides (Litt and Luty 1989; Weber and May 1989). Utilisation 
single nucleotide polymorphisms (SNP) as a genetic mapping tool has gained much 
interest recently. SNPs are most densely distributed variations in the human genome 
occurring approximately once in every 300 bp (minor allele frequency >1%), which 
make them an optimal choice for fine-scale mapping (Kruglyak and Nickerson 2001). As 
a result from HGP, 1.4 million SNPs in the human genome were identified, but since 
then this number has been multiplied to nearly 9 million (Sachidanandam et al. 2001; 
The International HapMap Consortium 2003; Hirschhorn and Daly 2005). The mutation 
rates of SNPs are much lower than those of microsatellites, which makes them more 
optimal for association analyses where co-segregation of a marker allele and disease is 
monitored for many generations (Kruglyak 1997). Yet another advantage is that several 
highly automated high-throughput methods for SNP genotyping have been developed 
(Syvänen 2005). 
The distances and marker ordering on genetic maps are based on meiotic recombination 
(θ), whereas physical maps quantify the distances in number of base pairs (bp). Most of 
the currently available genetic maps are based solely on microsatellites (NIH/CEPH 
Collaborative Mapping Group 1992; Sheffield et al. 1995; Broman et al. 1998), but the 
most recently published genetic map has incorporated also SNP markers (Kong et al. 
2002). The primary unit of distance along the genetic maps is centiMorgan (cM), which 
is equivalent to approximately 1% probability for recombination between two loci. As a 
rule of thumb, the equivalence between genetic and physical maps can be defined as one 
cM equalling one megabase (Mb)(Speer 1998). In reality, the recombination rate varies 
greatly along each chromosome from 0 to 9 cM per Mb (Yu et al. 2001).  
The construction of a novel type of genetic map is currently underway. This so called 
HapMap involves characterization of haplotype structure and haplotype tagging SNPs of 
entire genomes in different populations from Africa, Asia and Europe (The International 
HapMap Consortium 2003). The rationale behind this effort is discussed more closely in 
2.2.7. 
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2.2.3 Parametric linkage methods 
The aim of linkage analysis is to reveal those chromosomal loci, which harbour genetic 
variant(s) predisposing to a certain phenotype. Parametric linkage analysis (also referred 
to as model-based analysis) follows co-segregation of two genetic factors, the marker 
and the trait, at specific loci in pedigrees using the frequency of meiotic recombination 
as an estimate of genetic distance. The recombination fraction ranges from θ = 0 for loci 
right next to each other through θ = ½ for loci far apart or on different chromosomes. 
Two loci are said to be genetically linked when θ < ½, in other words the two loci do not 
segregate independently. The object of linkage analysis is to test whether an observed 
deviation from 50% recombination between two loci is statistically significant 
(Terwilliger and Ott 1994; Ott 1999). The statistical measure for linkage analysis is the 
logarithm of odds (LOD) score (Morton 1955): 
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LZ θθ , where 
Z (θ) = LOD score 
L (θ) = Likelihood function with given θ
L (0.5) = Likelihood function when θ = 0.5 
The likelihood function of the parametric linkage analysis requires specification of the 
disease parameters. These parameters include recombination fraction, marker allele-
frequencies, penetrance and phenocopy rate (probability of disease when 2, 1, or 0 
disease alleles are present), and the disease allele frequency. When complex diseases are 
considered, the true values of these parameters are unknown. The incorrect specification 
of the mode of inheritance may lead to loss of power and, consequently, type II errors 
(false negatives). Based on simulations, however, it has been proposed that parametric 
linkage analysis with both the recessive and dominant models is a robust method for 
detecting linkage in complex disorders, despite the fact that the model is not entirely 
correct (Greenberg et al. 1998; Xu et al. 1998; Abreu et al. 1999; Durner et al. 1999). 
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However, the number of statistical models tested should be modest, because a large 
number of tests increases the probability for type I errors (false-positives). Parametric 
LOD score analyses commonly also involve several analytical modifications when they 
are applied in the context of complex diseases including tests of heterogeneity, affected-
only analyses, and utilisation of liability classes (Xu et al. 1998). 
2.2.4 Non-parametric linkage methods 
Non-parametric methods (also referred to as model-free methods) are based on the allele-
sharing of affected related individuals. The simplest study design involves a large 
sample of affected sib-pairs (ASP). ASP methods observe how frequently two affected 
offspring share copies of the same parental alleles, i.e. alleles that are shared identical by 
decent (IBD). In the absence of linkage each affected sib-pair is expected to share 0, 1, 
and 2 alleles IBD with respective probabilities of 0.25, 0.50 and 0.25. If the marker locus 
is linked to a disease locus, ASPs will share marker alleles more often than expected by 
chance. The deviation from the expected sharing is tested statistically by using e.g. χ2 or 
mean tests (Ott 1999). Currently, the most widely used non-parametric method is NPL-
statistics implemented in the Genehunter-package, which overcomes several of the 
weaknesses evident in the earlier model-free methods. Like other non-parametric 
methods, NPL-statistics measures allele sharing among affected relatives within a 
pedigree. The main advantage is that NPL-statistics, specifically NPLall-statistics, can 
consider all affected relatives simultaneously rather than as a combination of all possible 
comparisons of pairs. Another advantage of Genehunter is that it is inherently multipoint 
method enabling the use of a large number of markers in one analysis (Kruglyak et al. 
1996). The main rationale for the wide use of non-parametric methods in the context of 
complex diseases is that there is no need for defining the mode of inheritance. Generally, 
NPL statistics tends to give overly conservative estimates of linkage when there is 
limited information available, but this problem is at least partly overcome by the 
multipoint approach (Kruglyak et al. 1996; Davis and Weeks 1997).  
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2.2.5 Determining the statistical significance in linkage analysis 
The point-wise significance level refers to a single test of the hypothesis of no linkage. 
This involves comparing the observed deviation at a specific locus with the probability 
that such a deviation is encountered by chance. The genome-wide significance level, by 
contrast, is the probability that one would encounter a deviation by change somewhere in 
a whole-genome scan (Lander and Kruglyak 1995). The traditional threshold for 
significance in two-point analyses of Mendelian disorders has been a LOD score of 3.0 
(Ott 1999). This value corresponds to 1000:1 odds for linkage, which means that the 
observed data is 1000-fold more likely to arise under the alternative hypothesis of 
linkage than under the null hypothesis of no linkage. It has been shown elsewhere, that 
the LOD score of 3.0 corresponds to a point-wise p-value of 0.0001 (Xu et al. 1998; Ott 
1999). Assuming that the genome-wide scan includes 400 markers and if these were 
treated as independent tests, the point-wise significance level of p = 0.0001 (LOD = 3.0) 
would correspond to a genome-wide significance level of α* = 1-(1-0.0001)400 = 0.039 
(Bonferroni correction).  
However, the tests in a genome-wide scan are not independent, but the tested markers 
are correlated with the nearby markers. According to Lander and Kruglyak (1995), the 
genome-wide significance level can be defined as follows: 
α* = 1-e-(C+2GX)α, where 
α* = genome-wide significance level 
α = point-wise significance level 
C = number of chromosomes 
G = the size of the genome in Morgans (M) 
X = 4.61 x LOD score 
If a genome-wide significance level of 0.05 is desired, the point-wise significance level 
should be α = 5 x 10-5, which corresponds to a LOD score of 3.3 (Lander and Kruglyak 
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1995). According to standards proposed by Lander and Kruglyak (1995) this is 
considered as significant evidence for linkage in general pedigrees. Two additional 
thresholds were suggested: a point-wise p-value of 1.7 x 10-3 corresponding to a LOD 
score of 1.9 for suggestive linkage, and a point-wise p-value of 0.05 corresponding to a 
LOD score of 0.59 for nominal evidence for linkage. For a sib-pair study, corresponding 
thresholds for nominal, suggestive, and significant linkage were suggested as 2.2, 3.6, 
and 5.4 (Lander and Kruglyak 1995). It is of interest that the approach by Lander & 
Kruglyak (1995) to determine significance levels has aroused criticism because they 
assume an infinitely dense set of markers and full marker information content, which is 
not the case in practice (Sawcer et al. 1997). 
Permutation testing is highly recommended when evaluating genome-wide significance 
levels (Lander and Kruglyak 1995; Sawcer et al. 1997). In this approach, a large number 
of genome-wide scans are simulated under the null hypothesis of no linkage anywhere in 
the genome. The pedigree structures, marker allele frequencies and intermarker distances 
are derived from the actual study. Genome-wide significance level is determined by 
testing how many times the empirically observed LOD score is exceeded by change in a 
large number of genome-wide scans. In permutation testing, a larger number of iterations 
result in a more reliable estimate of genome-wide significance (Sawcer et al. 1997).  
It is generally accepted that the replication of the initial significant linkage claim in an 
independent data set is required for the confirmed linkage (Lander and Kruglyak 1995). 
This has turned out to be a difficult task when dealing with complex diseases (Altmuller 
et al. 2001). Ascertainment protocols are used to increase the power of mapping, which 
means that the sample ascertained on a given phenotype is not representative of the 
population as a whole but, rather, some of the predisposing loci are likely to be over-
represented in the study sample. In a genome-wide scan, LOD scores are maximised in 
the ascertained sample over several parameters and over numerous point-wise tests 
throughout the genome. Therefore, genome-wide studies necessarily overestimate the 
effect size of any locus identified, which leads to the conclusion that the power needed 
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for replication will presumably be underestimated. Likewise, it is unlikely that the same 
subset of predisposing factors would have enriched in the replication sample and, thus, 
significantly larger sample size is needed detect this signal in an independent replication 
sample than that used in the original study (Göring et al. 2001). In addition, many 
simulation studies have shown that chance variation in location estimate of genetic 
linkage studies is substantial. The displacement decreases as the sample size and/or 
marker information content increases. Such inaccuracy clearly has consequences on 
replication attempts. It also makes it difficult to estimate the true location of the 
predisposing variant and to determine whether the two linkage peaks on the same 
chromosome from separate study samples represent the same genetic variant (Hovatta et 
al. 1998; Roberts et al. 1999). Also methodological differences across the studies may 
affect the variability of the results. The factors potentially improving the probability of 
replication include increased sample size, uniform study designs and focus on samples 
drawn from only one ethnic group (Altmuller et al. 2001; Göring et al. 2001). Based on 
the above-mentioned provisions, it is also clear that linkage cannot be reliably disproved 
by failure to replicate the original finding in other samples (Hovatta et al. 1998; Roberts 
et al. 1999). 
Even relatively large studies are likely to have a low power to map genes of modest 
effect by linkage analysis (Terwilliger and Göring 2000). It is commonly noted that the 
most powerful way to increase statistical power is to analyse original genotype data from 
several independent studies combined (Lander and Kruglyak 1995; Wise et al. 1999). 
Data sharing is not always possible in practice and that is why meta-analysis 
methodologies have been developed for genetic linkage analyses. Currently, the most 
widely used meta-analysis approach is the Genome Search Meta-Analysis (GSMA) 
method (Wise et al. 1999), but some other methods also exist (Dempfle and Loesgen 
2004). The GSMA method assesses evidence for linkage within specified chromosomal 
regions by splitting the chromosomes into bins of approximately equal length. These 
bins are ranked based on linkage evidence within each scan, the ranks for each bin is 
summed across genome-wide scans, and finally the summed rank is compared to its 
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probability distribution under null hypothesis. The advantage of this approach is that it 
enables comparison of genome-wide scans, which have used different family structures, 
marker sets, and statistical analysis methods (Wise et al. 1999).  
2.2.6 Association mapping 
Association mapping can be divided into direct and indirect methods. In direct 
association analysis, the variant itself is thought to predispose to the disease. In practice, 
this method is confined only to analyses of known functional variants in candidate genes. 
The indirect method, in contrast, employs linkage disequilibrium (LD), which is a 
phenomenon of non-random association of alleles at adjacent loci (Collins et al. 1997; 
Kruglyak 1999). The fundamental idea behind the LD mapping is that the affected 
individuals in the population have inherited the same ancestral predisposing allele 
identical-by-descent (IBD). When a new allele is incorporated into a population and is 
transmitted to the next generation, the haplotype of polymorphisms are brought along 
with it. LD around newly generated allele decays through recombination over time, but 
the ancient genetic architecture may still be detectable after several generations 
(Terwilliger and Göring 2000). Some of the early examples introducing LD mapping to 
medical genetics include studies of diastrophic dysplasia (DTD; MIM 222600) 
(Hastbacka et al. 1992) and infantile-onset spinocerebellar ataxia (IOSCA; MIM 
271245), where only four affected individuals from two consanguineous pedigrees were 
sufficient for the initial disease gene localisation (Nikali et al. 1995).  
The rationale for the use of association-based methods as a primary tool in mapping of 
complex diseases comes from the recognition that linkage-based methods have a low 
power to map susceptibility genes with low genotypic relative risk. In such cases, 
association analyses are more powerful than linkage-based methods, at least in theory 
(Risch and Merikangas 1996). In addition, linkage-based methods are not suitable for 
fine-scale mapping. Since the direct association method is confined only to some special 
cases, the crucial question is whether susceptibility loci could be detected through LD 
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between the disease variant and a nearby marker (Collins et al. 1997). Based on the 
common disease/common variant (CD/CV) hypothesis, genetic susceptibility for 
common diseases is often influenced by relatively common disease predisposing alleles. 
In cases consistent with CD/CV hypothesis, common alleles have a modest impact on 
individuals, but a strong effect on human population (Lander 1996; Chakravarti 1999; 
Reich and Lander 2001). This assumption is the prerequisite for success in LD-based 
association mapping of common disorders.  
The currently available empirical evidence is not sufficient to estimate how commonly 
the CD/CV hypothesis holds true. There are now several examples of variants conferring 
susceptibility for a common disease, but most of these are rare subtypes, which have 
modest impact at the population level (Risch 2000). There are, however, also some 
known cases, in which common variant predisposes to a common phenotype 
(Lohmueller et al. 2003). Based on theoretical models, it seems that in general the loci 
with a strong effect would have higher mutation rates and lower population frequencies, 
whereas susceptibility genes with modest effect would be more common and have lower 
mutation rates (Pritchard 2001; Reich and Lander 2001; Pritchard and Cox 2002). So far, 
however, LD mapping has been most successful in identification and restriction of the 
loci for rare recessive diseases in isolated populations, which have small number of 
founders and have undergone a rapid expansion (Peltonen et al. 1999). 
2.2.7 Structure of LD in the human genome 
Considerable attention has been focused on to what extent LD is observed in the human 
genome. The extent of LD relates to the question, how dense marker maps are needed 
for the association analysis. It is important to minimise the number of markers used 
while maximising information content due to limited genotyping capacity and the fact 
that multiple statistical tests need corrected p-values. Several measures exist for 
quantifying the LD, of which the most commonly used are D, absolute value of D’, and 
r2 (Ardlie et al. 2002; Weiss and Clark 2002).  
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The empirical evaluations of the extent of LD in the human genome have involved a 
wide range of strategies including different populations, chromosomal regions, marker 
types, and marker densities, as well as measures for reporting LD, which makes the 
comparison of the results from these efforts difficult. Generally, the empirical studies 
have concluded that LD is extremely variable in several respects, differing markedly 
across the genomic regions and populations (Ardlie et al. 2002). The average extent of 
useful LD seems to extend 10-30 kb in European populations and markedly less in the 
African populations (Reich et al. 2001; Ardlie et al. 2002; Shifman et al. 2003). In 
rapidly expanded isolated populations, e.g. in the Finnish population, haplotypes 
extending up to 13 cM have been reported around rare disease alleles (Peltonen et al. 
1999). However, the alleles with high frequency (>5%) may not express significantly 
higher LD in recently expanded isolated populations than in more mixed populations 
(Kruglyak 1999; Eaves et al. 2000; Taillon-Miller et al. 2000). On the other hand, small 
constant sized populations (Laan and Paabo 1997; Kaessmann et al. 2002) and small 
sub-isolates (Varilo et al. 2000; Varilo et al. 2003) seem to express elevated levels of 
LD. Thus, they could be better suited for the initial coarse mapping of diseases caused 
by common variants than the traditional isolated populations, given that the population 
size allows for the collection of a sufficient number of samples for the statistical analyses 
(Kaessmann et al. 2002; Varilo et al. 2003). Consistently with this idea, Reich and 
colleagues (2001) suggested that fine-scale mapping should be performed in African 
populations, because they show significant LD only over very short intervals and 
therefore could better refine the critical region. Therefore, gaining access to multiple 
populations with divergent demographic histories would theoretically be an optimal 
setting for LD mapping studies, but such an approach obviously has some practical 
limitations. 
There has recently been a shift from quantifying usable levels of LD to studying the 
structure of LD. Despite the apparent complexity of observed LD patterns, recent studies 
have proposed that the underlying structure of LD in the human genome can be modelled 
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as a series of discrete haplotype blocks, which are flanked by regions of recombination 
hot spots (Daly et al. 2001; Jeffreys et al. 2001; Patil et al. 2001; Dawson et al. 2002; 
Gabriel et al. 2002; Phillips et al. 2003). Gabriel and colleagues (2002) identified 
haplotype blocks with an average block size of 11 and 22 kb in African and non-African 
samples, respectively. It is noteworthy that only a few haplotypes per block were 
generally observed, and a large portion of the haplotypes seemed to be shared across the 
populations (Gabriel et al. 2002). Even if some regions in the genome fit well with the 
haplotype block model, LD seems to be more complicated in large portions of the 
genome. All currently available studies have reported some large blocks extending >100 
kb, but also regions of no detectable LD over small distances (<1kb) (Daly et al. 2001; 
Patil et al. 2001; Dawson et al. 2002; Gabriel et al. 2002; Phillips et al. 2003).  
Some of the basic assumptions in the haplotype block model are still unclear. Recent 
studies support the fact that recombination is often clustered on hot spots, but it is yet 
unknown to what extent recombination is concentrated in that way (Arnheim et al. 2003; 
Zhang et al. 2003). It is not clear to what extent other factors than recombination, such as 
gene conversion or genetic drift, affect the LD block structure (Ardlie et al. 2001; Weiss 
and Clark 2002; Zhang et al. 2003). If the recombination hot spot model is the 
predominant mechanism for block formation, the block boundaries should be strongly 
correlated across different populations. Otherwise, the block structure has to be 
empirically determined for each population (Wang et al. 2002; Zhang et al. 2003). 
Furthermore, the use of only common SNPs, sparse marker maps and small sample sizes 
may have led to overestimation of block lengths in the empirical haplotype block 
analyses and it has been argued that only a few of the currently available studies satisfy 
the criteria for the optimal study design (Wang et al. 2002; Zhang et al. 2003; van den 
Oord and Neale 2004).  
The haplotype-block model may have important implications for large-scale association 
studies, since it indicates a simple rationale for how to select SNP markers. The main 
haplotypes could be labelled with a small number of haplotype-tagging SNPs (htSNPs) 
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sufficient to distinguish between the main haplotypes within a block. Thus, most of the 
variation in the genome could be traced with a limited number of markers (Daly et al. 
2001; Patil et al. 2001; Dawson et al. 2002; Gabriel et al. 2002; Phillips et al. 2003). The 
United States National Human Genome Research Institute (NHGRI) and Wellcome 
Trust have initiated an effort, called the International HapMap project, which aims to 
create a genome-wide map of haplotype-blocks in several populations. This effort is 
hoped to facilitate the positional cloning of common variants by genome-wide 
association studies (The International HapMap Consortium 2003; Hirschhorn and Daly 
2005). The success of the HapMap tool is highly dependent on the CD/CV hypothesis, 
and it is probably not a powerful tool for mapping rare and geographically localised 
variants (Weiss and Clark 2002; van den Oord and Neale 2004). Yet, even if novel high-
throughput technologies allow genotyping of massive numbers of SNP markers per 
sample (Syvänen 2005; Hirschhorn and Daly 2005), huge sample sizes would be needed 
to reach statistical significance in a genome-wide association study due to multiple 
statistical testing. Various estimates of the amount of SNPs needed to extract 
information of genome have been put forward and they reach from 300 000 to 3 million 
or more. The HapMap concept involves several unanswered questions, and its relevance 
for mapping of common disease genes, at least at the genome-wide scale, remains 
elusive.
2.2.8 Study designs in association mapping 
The case-control strategy, which compares the allele-frequencies between the cases and 
controls, has traditionally been the most widely applied approach in association analyses 
(Figure 4). The advantage of this strategy is that such studies are relatively easy to set 
up. On the other hand, case-control studies are prone to false-positive associations 
caused by population stratification and systematic errors in control sampling. The careful 
matching of cases and controls is crucial, since any differences in allele-frequencies lead 
to positive associations. Control ascertainment can be improved by using a prospective 
cohort study, where a large number of individuals are collected prior onset of the 
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disease, and the association between cases and controls is tested after the age of disease 
onset. In this way, bias in control population selection is avoided. However, such study 
design requires much more resources, larger sample sizes, and longer time than the 
traditional case-control design (Cardon and Bell 2001; Ott 2004). Alternatively, 
population stratification may be assessed by using data from a series of unlinked 
markers. A method entitled genomic control compares the chi-square statistics for the 
test data with the chi-square obtained on unlinked markers, which results in corrected 
chi-square statistics (Pritchard et al. 2000). 
Methods using family-based controls have been developed to avoid bias in control 
ascertainment. In haplotype-relative risk (HRR) method, parental alleles are classified 
into those transmitted to affected children and those not transmitted. HRR compares 
allele and genotype frequency between the proband group and a control group, which is 
constructed from non-transmitted alleles. The relative risk is assessed by chi-square 
statistics (Falk and Rubinstein 1987; Ott 1999). The transmission disequilibrium test 
(TDT) is a modification of HRR, which tests linkage in the presence of LD using data 
consisting of parents and the affected offspring. The frequency of transmitted alleles is 
compared with non-transmitted parental control alleles, and the statistical significance of 
the deviation is tested (Spielman et al. 1993; Spielman et al. 1994; Spielman and Ewens 
1996). Various extensions of TDT are currently available to overcome the problems 
caused by missing or homozygous parental data, eliminate the effect of linkage when 
multiple siblings are present in a family, and to include quantitative traits in the analyses 
(Clayton 1999; Abecasis et al. 2000; Göring and Terwilliger 2000; Horvath et al. 2001). 
There are also methods to combine information from several adjacent SNP markers to 
construct haplotypes, which can be used as multiallelic markers in the family-based 
association analyses (Clayton 1999; Horvath et al. 2001). The major drawback in all the 
family-based association methods is clearly that parental samples are not always 
available, especially in late-onset diseases. It has also been suggested that TDT-based 
tests are more susceptible to false-positive results due to technical artefacts than case-
control studies (Hirschhorn and Daly 2005). 
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Figure 4. Comparison of different study designs in genetic mapping. Linkage 
analysis tests correlation of marker alleles and phenotype within families. Association 
analyses, by contrast, test correlation of marker alleles and phenotype between the 
families.  
2.2.9 Validity of genetic associations 
Promising associations have recently emerged for common complex diseases, but the 
inability to replicate the original findings is still the predominant phenomenon in the 
genetic association studies. In principle, the inconsistency may be due to false negative 
studies, false positive studies, or true variability in association among different 
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populations (Lohmueller et al. 2003). Some of the difficulties in the interpretation of the 
reported associations are listed below. 
Association analyses commonly consider candidate genes, which can be divided into 
positional and hypothesis-driven candidates. Positional candidates are selected because 
they are located in a genomic region that has been identified by mapping studies. 
Hypothesis-driven candidates, by contrast, are selected because they fit into a proposed 
model of the physiology of the phenotype (Glatt and Freimer 2002). The findings from 
these two types of studies should be considered somewhat differently. The hypothesis-
driven candidates have been selected based on a limited knowledge of relevant pathways 
for the disease pathogenesis, and thus the vast majority of functional candidates are 
excluded from these analyses. Therefore, the prior probability is in many cases 
extremely low, which implies that highly convincing evidence is needed to reject the null 
hypothesis. For positional candidates, prior probability is higher due to advance evidence 
from mapping studies (Owen et al. 1997; Glatt and Freimer 2002; Ott 2004). 
Many of the problems in association studies relate to the sample-size. Studies with small 
or moderate samples are prone to random error and often provide wide confidence 
intervals for any significant conclusions. Generally, the genetic determinants are thought 
to be of modest effect, which means that large samples are required for convincing 
associations (Owen et al. 1997; Cardon and Bell 2001; Glatt and Freimer 2002). 
Furthermore, as in linkage analysis, it has been shown that the estimate of the genetic 
effect in the first positive report is usually biased upward complicating the replication 
attempts in the samples that are of similar size as in the original study (Göring et al. 
2001; Lohmueller et al. 2003). Meta-analyses have become popular methods also in 
genetic association studies to increase statistical power and estimate significance levels 
across published studies (Munafo and Flint 2004).  
The significance level is often difficult to specify in the presence of multiple testing and 
low prior probability. It is obvious, however, that more stringent significance level 
criteria than the conventional p<0.05 are needed for convincing associations (Ott 2004). 
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Typically, all the statistical tests performed are not reported or the reported associations 
are not corrected for multiple testing. This inevitably leads to overestimation of the 
significance (Owen et al. 1997; Ott 2004). The problem is multiplied by the recent 
emergence of haplotype-based association methods. Usually numerous combinations of 
tightly linked SNPs are tested, each with a possibility of observing type I error. On the 
other hand, traditional statistical corrections, such as Bonferroni correction, may be 
overly conservative when highly correlated markers are tested (Cardon and Bell 2001; 
Hennah et al. 2004). Production of empirical p-values overcomes some of the multiple 
testing problems, but the results are dependent upon the arbitrarily chosen number of 
permutations to be carried out (Hennah et al. 2004). It is also evident that negative 
results from the replication studies are not published as frequently as positive findings. 
This leads to publication bias, meaning that significant p-values tend to be over-
represented in the literature (Terwilliger and Weiss 1998; Ott 2004).  
Consideration of the haplotypes or LD across a gene of interest has started only recently. 
Failing to do so will likely produce type II error or result in inconsistent results across 
the studies (Ott 2004). Effect of LD on the sample size required to detect association is 
exemplified in Figure 5. 
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Figure 5. Effect of LD on the sample size required in association mapping. D’ values 
ranging from 0.5 to 1.0 are show on the X-axis and number of cases and controls 
required to detect association at significance levels of 0.1, 0.05, 0.01 and 0.001 (95% 
power) are shown on the Y-axis. The arbitrarily chosen parameters are as follows: 
disease-allele frequency = 0.3, minor allele frequency of the marker = 0.3, population 
prevalence = 0.01, genotype relative risk = 1.5. Simulations were performed using the 
Genetic Power Calculator (Purcell et al. 2003). 
Probably the only way either to confirm or disprove the reported associations is to 
perform several independent replication studies, each analysing a full spectrum of allelic 
variants within the associated region. The accumulated information, along with 
functional information, should eventually reveal whether the associations are valid or not 
(Hennah et al. 2004; Ott 2004).  
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2.2.10 Value of population isolates in the complex disease mapping
Isolated populations, such as the Finnish population, have been extremely useful for 
mapping rare Mendelian diseases. By definition, these populations are founded by a 
relatively small number of individuals and remained isolated due to e.g. cultural and/or 
geographical factors. Several factors, such as a high degree of inbreeding, rapid 
expansion, population bottlenecks and genetic drift, have modified the genetic 
background leading to the reduced genetic diversity and enrichment of some alleles 
(Peltonen et al. 2000). In the Finnish population this is exemplified by enrichment of a 
special set of monogenic disorders caused by one or few ancestral mutations (the so 
called Finnish disease heritage) and absence of some diseases, which are common 
elsewhere. When the vast majority of cases are caused by the same ancestral mutation, 
LD is observed in significant intervals, thereby greatly facilitating the disease gene 
identification by haplotype-based methods (Peltonen et al. 1999; Norio 2003a; Norio 
2003b).
For common alleles, the situation is less straightforward. Even if the number of founders 
is relatively small, common alleles will enter the founder population so many times that 
the length of shared haplotypes around these alleles will be indistinguishable from that 
of the much larger ancestral population. This is why significantly elevated levels of LD 
have not generally been detected around common alleles in the isolated populations 
(Kruglyak 1999; Eaves et al. 2000; Taillon-Miller et al. 2000; Hirschhorn and Daly 
2005). However, population isolates offer some other advantages, which might prove 
important in the genetic mapping of many common diseases. First, the people in many 
isolates share a common environment and culture, which are potentially important 
factors in the development of many complex diseases. Second, it is easier to standardize 
diagnostic criteria and thus markedly decrease the phenotypic heterogeneity. In some 
isolated populations, clinical information is systematically collected into the health-care 
records, which are usually available for research purposes. Third, it is in some cases 
possible to identify small subisolates or reconstruct large pedigrees based on the 
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population registries. This approach should greatly increase the genetic homogeneity of 
the sample. Finally, the benefits of the reduced genetic heterogeneity in isolates will 
certainly hold in the cases where rare alleles confer significant increase in susceptibility 
to complex diseases (Peltonen et al. 2000). 
2.3 Genetics of autism spectrum disorders 
2.3.1 Establishing the genetic component in Autism Spectrum Disorders 
In a family study by Bolton and colleagues (1994) 2.9% of autistic probands’ siblings 
had autism and a further 2.9% had features of the more broadly defined PDD (atypical 
autism or AS). Therefore, assuming a prevalence rate of 2/1000 the sibling risk 
compared with the risk in the general population (λs) would be around 15-30 for autism 
indicating strong familial clustering of the disorder. Twin studies have suggested that 
familial clustering is mainly due to genetic factors. Bailey and colleagues (1995) re-
analysed the twin pairs originally included in the two studies by Folstein and Rutter 
(Folstein and Rutter 1977b; Folstein and Rutter 1977a) and expanded the sample to 
include 25 MZ and 20 DZ twins. A strong genetic component in autism was established 
with 60% MZ concordance and 0% DZ concordance for narrow phenotypic definition 
for autism. The concordance rate of 0% for DZ-twins is likely to be an underestimate 
due to the small sample size used, and the true DZ-twin concordance is probably similar 
to the nontwin-sib rate. The corresponding figures for MZ and DZ twins with broad 
spectrum of cognitive or social abnormalities was 90% and 10%, respectively. (Bailey et 
al. 1995). Even higher MZ concordance rates were reported in a study by Steffenburg 
and colleagues (1989). In their sample collected from Nordic countries, 91% (10/11) of 
MZ twins and 0% (0/10) of DZ twins were concordant for autism. Also, several other 
twin studies have been published in autism but they have generally failed to include 
sufficient number of cases or they have suffered from inappropriate methodological 
procedures (see, e.g. Ritvo et al. 1985).  
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Several studies have provided evidence that a complex mode of inheritance with 
multiple interacting genes and environmental factors is most likely for autism. The first 
evidence for this is a rapid cut-off in MZ and DZ twin concordance rates (Bailey et al. 
1995) combined with further cut-off in both autism and broader phenotype going from 
first-degree relatives to second-degree relatives (Jorde et al. 1990). Furthermore, the less 
than 100% risk for MZ twins indicates that also other than genetic factors play a role 
(Bailey et al. 1995). The segregation analyses performed in autism have rejected a single 
locus model and supported the fact that a polygenic model is most likely (Jorde et al. 
1991; Pickles et al. 1995). Pickles and associates (1995) concluded that a three-gene 
epistatic model is most likely, even if the range could be between two and ten. In their 
report of a genome-wide scan in autism Risch and colleagues (1999) proposed that more 
than 15 loci might contribute to the aetiology of autism. 
Evidence concerning familial aggregation and genetic contribution to AS is still scarce. 
However, several case reports, including the original report by Asperger (1944), have 
noted that AS-like problems in social interactions are frequently present in AS 
individuals’ family members (Asperger 1944; Burgoine and Wing 1983; Bowman 1988; 
Gillberg 1989; Volkmar et al. 1996; Volkmar et al. 1998; Folstein and Santangelo 2000). 
The preliminary results from the Yale Asperger Project with 99 families indicate that 
there was a positive family history of AS or similar condition in 46% of the families 
(Volkmar et al. 1998). Gillberg (1989) described 23 AS families, in which 28% of the 
parents fulfilled the criteria for a broad autism phenotype or AS. Thus, the preliminary 
evidence available suggests that familial aggregation of AS might be even stronger than 
that of autism (Gillberg 1989; Volkmar et al. 1998). Furthermore, autism and AS 
commonly exist in the same families suggesting that at least in some cases common 
aetiological factors might predispose to these syndromes (Gillberg 1989; Volkmar et al. 
1998; Folstein and Santangelo 2000). 
48
2.3.2 Known genetic aetiologies associated with autism 
Autism is over-represented as part of the behavioural phenotype in several syndromes of 
genetic origin (Table 3). Some of these monogenic causes may lead to a phenotype, 
which is indistinguishable from the idiopathic cases, whereas in some other cases the 
autistic-like features are only a one component of the phenotype. Known genetic 
syndromes together with chromosomal abnormalities constitute approximately 10-15% 
of autism cases (Bailey et al. 1996; Chakrabarti and Fombonne 2001; Folstein and 
Rosen-Sheidley 2001). However, the relevance of these genes to the understanding of 
the pathogenesis of idiopathic autism is yet uncertain.  
Fragile X syndrome (FRAXA). The phenotype of fragile X syndrome (MIM 309550) 
includes moderate to severe mental retardation, macroorchidism, large ears, a prominent 
jaw, and high-pitched jocular speech. Males with FRAXA have also numerous autistic-
like features (Feinstein and Reiss 1998; Sabaratnam et al. 2003). Fragile X syndrome is 
caused by mutations in fragile X mental retardation 1 gene (FMR1) that result from a 
CGG trinucleotide expansion in the 5’ untranslated region and lead to DNA methylation 
and lack of transcription (Verkerk et al. 1991; Feinstein and Reiss 1998). FMR1 gene 
encodes an RNA-binding protein FMRP (fragile X mental retardation protein), which 
influences synaptic plasticity through regulation of mRNA transport and local protein 
synthesis at synapses using micro RNA (miRNA) pathway as the main mechanism (Jin 
et al. 2004). Varying frequencies of FRAXA have been reported in autism. Earlier 
studies reported only a little association, whereas more recent studies have shown 
frequencies ranging from 2 to 8% (Bailey et al. 1996; Feinstein and Reiss 1998; Wassink 
et al. 2001; Muhle et al. 2004). ASDs are relatively common in the group of fragile X 
patients with up to 30% of the patients with FRAXA fulfilling the criteria for ASD 
(Feinstein and Reiss 1998; Rogers et al. 2001; Muhle et al. 2004).  
Tuberous sclerosis complex (TSC). The tuberous sclerosis complex (MIM 191100; 
191092; 605284) is a dominantly inherited disease characterized by the presence of 
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hamartomata in multiple organ systems. The clinical features include epilepsy, learning 
difficulties, behavioural problems, as well as skin and renal lesions. It has been estimated 
that as many as from 25 to 50% of patients with TSC fulfil the criteria for autism, 
whereas the prevalence of TSC in autism has been reported as 1 – 4% (Smalley 1998; 
Curatolo et al. 2004; Wiznitzer 2004). Mutations in two different tumour suppressor 
genes, TSC1 encoding hamartin protein and TSC2 encoding tuberin protein, may lead to 
TSC (The European Chromosome 16 Tuberous Sclerosis Consortium 1993; van 
Slegtenhorst et al. 1997). These proteins form a TSC1-TSC2 complex, which is involved 
in regulation of cell growth and proliferation (Pan et al. 2004). It is yet unclear whether 
the autistic features in TSC are caused by the presence of a non-specific disruption of 
brain function related to complications of TSC, such as seizures, MR, and presence of 
tubers in the temporal lobes, or whether the autism is caused by a distinct molecular 
mechanism involving TSC1-TSC2 complex (Wiznitzer 2004).
Neurofibromatosis (NF1). Type I neurofibromatosis (MIM 162200) is an autosomal 
dominant disorder characterized by cafe-au-lait spots and fibromatous tumours of the 
skin. NF1 gene mutated in type 1 neurofibromatosis encodes a tumour suppressor called 
neurofibrin, which functions as a negative regulator of Ras, a fundamental protein 
controlling cell proliferation. Impaired neurofibrin function leads to elevated Ras activity 
and, consequently, increased cell proliferation (Cawthon et al. 1990; Dasgupta and 
Gutmann 2003). Neurofibromatosis appears to overlap with small fraction of autism 
cases, but greatly varying frequencies have been reported due to small sample sizes in 
the studies. However, the frequency of neurofibromatosis in autism seems to be much 
lower than those of FRAXA or tuberous sclerosis (Williams and Hersh 1998). 
NLGN4 and NLGN3 mutations. Two X-chromosomal members of the neuroligin gene 
family, NLGN3 and NLGN4, have been shown to be mutated in some patients with 
ASDs. Two affected males with autism and AS in a Swedish family had an insertion in 
NLGN4, which led to premature truncation of the protein (D396X). In another Swedish 
family with autism and AS, an R451C substitution in NLGN3 was identified (Jamain et 
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al. 2003). In addition, a truncating NLGN4 mutation (D429X) was later reported in a 
large family, where mental retardation with or without ASDs segregated X-
chromosomally (Laumonnier et al. 2004).  
Neuroligins were originally isolated as splice site-specific ligands of β-neurexins in the 
rat brain (Ichtchenko et al. 1995). The neuroligin gene family consists of five genes in 
humans: neuroligin-1 (NLGN1) located at 3q26, neuroligin-2 (NLGN2) located at 17p13, 
neuroligin-3 (NLGN3) located at Xq13, neuroligin-4 (NLGN4) located at Xp22, and 
neuroligin-4Y (NLGN4Y) located at Yq11. Neuroligin genes encode 816–863 amino acid 
transmembrane proteins which are composed of five distinct domains: an N-terminal 
cleaved signal peptide, a large extracellular domain homologous to acetylcholinesterases 
(AchE), a short linker domain, transmembrane domain, and a cytosolic region 
(Ichtchenko et al. 1995; Ichtchenko et al. 1996; Bolliger et al. 2001). The extracellular 
esterase-domain lacks an active site serine suggesting that it is not catalytically active 
(Ichtchenko et al. 1995).  
The rodent neuroligins 1, 2, and 3 have been shown to be expressed at high levels only 
in the brain (Ichtchenko et al. 1995; Ichtchenko et al. 1996; Song et al. 1999). Similarly, 
human neuroligins are expressed in the brain with no considerable differences in the 
regional distribution (Song et al. 1999; Jamain et al. 2003). However, at least human 
NLGN4 has been shown to be expressed also in heart, liver, skeletal muscle, and 
pancreas (Bolliger et al. 2001). Neuroligin-1 expression has been shown to be low in 
embryonic brains but increase dramatically after birth. The expression was again reduced 
during the period when most synapses are already formed, but some level of expression 
seems to persist throughout adulthood (Ichtchenko et al. 1996; Song et al. 1999; 
Scheiffele et al. 2000). It has been suggested that such an expression pattern might 
reflect the involvement of neuroligins in the synaptic remodelling processes or in the 
regulation of the size and strength of synaptic connections by inducing new presynaptic 
specializations or by stabilizing pre-existing structures (Scheiffele et al. 2000).  
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Neuroligins have several well-characterized interactions. As noted above, at the 
presynaptic side neuroligins bind to β-neurexins in a Ca2+-dependent manner 
(Ichtchenko et al. 1995; Comoletti et al. 2003). At the postsynaptic density, neuroligins 
interact with PDZ-domains (PSD-95-Drosophila discs-large tumour suppressor protein-
zona occludens-1) of several proteins, including PSD-95 (post synaptic density 95) and 
S-SCAM (synaptic scaffolding molecule) (Irie et al. 1997; Hirao et al. 1998; Meyer et al. 
2004). However, the PSD-95 or β-neurexin interactions are not needed for the targeting 
of the neuroligins to synapses, but instead, neuroligins have an intracellular domain that 
is essential for postsynaptic targeting (Dresbach et al. 2004). 
Neuroligins seem to be capable of triggering the de novo formation of presynaptic 
structures at glutamatergic synapses. Scheiffele and colleagues (2000) observed 
development of several presynaptic structures when CNS neurons were co-cultured with 
non-neuronal cells expressing neuroligins in vitro. These changes involved clustering of 
synaptic vesicles within axons and several functional and morphological changes typical 
for neuron-neuron synapses. Such changes are not typically observed when neurons are 
contacted with non-neuronal cells. The neuroligin activity seemed to require specific 
sequences in the extracellular, acetylcholinesterase-homologous domain of the protein. 
In addition, the neuroligin-activity was inhibited by adding soluble β-neurexin indicating 
that β-neurexins were primary candidates for mediating the neuroligin functions 
(Scheiffele et al. 2000). It was later shown that neuroligins form oligomers and these 
oligomers recruit neurexins to newly forming synaptic sites. A two-step model of 
neuroligin function was proposed, in which postsynaptic neuroligin oligomers initially 
cluster axonal neurexins. In response to this clustering, neurexins nucleate the assembly 
of a cytoplasmic scaffold to which the exocytotic apparatus is recruited (Dean et al. 
2003). Neurexins are directly coupled to synaptotagmins, which are core molecules of 
synaptic vesicle machinery that regulate neurotransmitter exocytosis (Hata et al. 1993). 
Therefore, neuroligin - β-neurexin interaction may activate an array of presynaptic 
molecular responses, leading to structural re-organisation of the presynaptic 
compartment (Prange et al. 2004). 
52
There is now evidence that neuroligins might also be involved in mediating the synapse 
formation at the inhibitory synapses. Neuroligins-1, -3, and –4 are localized exclusively 
at the postsynaptic side of the excitatory synapses (Song et al. 1999; Graf et al. 2004). 
Neuroligin-2, by contrast, has been shown to localize also at the inhibitory synapses 
(Graf et al. 2004; Varoqueaux et al. 2004; Chih et al. 2005). It has been shown that 
mislocalized expression of neuroligin-2 disperses the postsynaptic proteins and disrupts 
synaptic transmission at both inhibitory and excitatory synapses (Graf et al. 2004). 
Furthermore, neuroligin over-expression seems to increase both excitatory and inhibitory 
synaptic contacts (Prange et al. 2004; Chih et al. 2005). Finally, knockdown of 
neuroligin function by the RNA interference (RNAi) method reduces the number of both 
excitatory and inhibitory synapses. The effect concerning inhibitory synapses are more 
pronounced when the function of neuroligin-2 is suppressed (Chih et al. 2005). Thus, it 
seems that neuroligin - β-neurexin interaction is a major component in synapse 
formation mediating both GABAergic and glutamatergic synaptogenesis (Graf et al. 
2004; Prange et al. 2004). Furthermore, based on RNAi studies and the neuroligin 
knock-out mouse (for which the phenotype has not been published), it seems that 
different neuroligin isoforms are able to compensate for each other’s functions at least to 
some extent (Song et al. 1999; Chih et al. 2005). 
Multiple lines of evidence indicate that the reported NLGN3 and NLGN4 mutations have 
deleterious effects at the molecular level. First, both of the truncating mutations reported 
by Jamain and co-workers (Jamain et al. 2003) and Laumonnier and co-workers 
(Laumonnier et al. 2004) involve deletion of the AchE-homologous domain, which is 
required for oligomerization and the synapse promoting activity of neuroligins (Dean et 
al. 2003). Second, Comoletti and colleagues (2004) reported markedly diminished β-
neurexin binding activity of the R451C mutation in NLGN3 compared to the wild-type 
protein. Third, both R451C mutation in NLGN3 and D396X mutation in NLGN4 lead to 
retention of the protein in the endoplasmic reticulum, and cell surface levels of the 
mutants are significantly lower than the levels of the wild-type protein. Finally, neither 
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of these mutants seem to promote presynaptic differentiation (Chih et al. 2004; 
Comoletti et al. 2004). Although the functional studies support that NLGN3 and NLGN4
mutations may be causative for autism, they occur at a low frequency. The two original 
mutations were identified among 158 samples from independent families with autism or 
AS (Jamain et al. 2003). Subsequently, Vincent and colleagues (2004) and Gauthier and 
colleagues (2004) performed mutation analysis of NLGN3/NLGN4 genes by using 
samples of 196 and 96 autistic probands, respectively. No causative mutations were 
identified in either of the samples. Thus, the currently reported frequency of either 
NLGN3 or NLGN4 mutations is around 0.4%. 
Other syndromes associated with autism. Several other rare syndromes having autistic 
behavioural pattern have been reported (Table 3). Phenylketonuria (PKU; MIM 261600) 
is the earliest reported association between a Mendelian condition and autism but it 
seems to occur in a very low frequency (Folstein and Rosen-Sheidley 2001; Baieli et al. 
2003). Currently, the association is probably non-existent due to effective treatment of 
the PKU (Folstein and Rosen-Sheidley 2001). In addition, the phenotypes of e.g. Smith-
Lemli-Opitz syndrome (SLOS; MIM 270400), Cornelia de Lange syndrome (CDLS; 
MIM 122470), Angelman syndrome (MIM 105830), Prader-Willi syndrome (PWS; 
MIM 176270), and Timothy syndrome (TS; MIM 601005) are associated with autistic 
behaviour (Steffenburg et al. 1996; Berney et al. 1999; Tierney et al. 2000; Splawski et 
al. 2004; Veltman et al. 2004). Furthermore, some female cases with atypical autism 
phenotype have been reported to have MECP2 or CDKL5/STK9 mutations originally 
associated with Rett syndrome (Carney et al. 2003; Weaving et al. 2004). 
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Table 3. Syndromes and single gene mutations associated with autistic behavior. Note that for most aetiologies it is difficult to 
give reliable frequency estimates due to the rarity of the overlap.  
              
Etiology MIM Characteristic phenotype Defective  Chromosomal Mode of inheritance Frequency 
   gene location  in autism 
              
   
Angelman syndrome 105830 MR, ataxia, hypotonia, characteristic facial features,  UBE3A 15q11.2 Mostly sporadic - 
  Epilepsy, absence of speech, predominant smiling and    
  laughter    
Cornelia de Lange  122470 Characteristic facies in association with prenatal and NIPBL 5p13.2 Mostly sporadic -
Syndrome postnatal growth retardation, MR, upper limb anomalies 
Fragile X syndrome 30950 Moderate to severe MR, macroorchidism, large ears, FMR1 Xq27.3 X-chromosomal  2-8% 
  prominent jaw, high-pitched jocular speech    
Neurofibromatosis 162200 Cafe-au-lait spots and fibromatous tumours of the skin, NF1 17q11.2 Autosomal dominant 0.3-6% 
(Type I) abnormalities of the skeleton and CNS, learning difficulties 
NLGN3/NLGN4 300425 Autism, AS, non-specific MR NLGN3 Xq13.1 X-chromosomal  Few cases 
mutations 300495  NLGN4 Xp22.3  reported 
Phenylketonuria 261600 MR, characteristic odour, light pigmentation, peculiarities  PAH 12q23.2 Autosomal recessive -
of gait, stance, and sitting posture, eczema, epilepsy 
Prader-Willi  176270 MR, obesity, hypogonadism, hypotonia, short stature, unknown 15q11-13 Mostly sporadic - 
syndrome  small hands and feet, hypopigmentation, characteristic    
  facial features    
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Table 3 continued. 
              
Etiology MIM Characteristic phenotype 
Defective 
gene Chromosomal Mode of inheritance Frequency 
    location  in autism 
              
Rett syndrome/ 312750 Loss of acquired skills between ages 6 and 30 months, MECP2 Xq28 X-chromosomal  Few atypical 
Rett variants communication dysfunction, social withdrawal, deceleration CDKL5 Xp22.13 cases
of head growth, stereotypic hand movements, gait appraxia/ reported  
ataxia
Smith-Lemli-Opitz 270400 MR; dysmorphic features, occasionally malformations DHCR7 11q13.4 Autosomal recessive - 
syndrome  in the brain, lung, heart, and gastrointestinal tract    
Timothy syndrome 601005 Arrhythmia, congenital heart disease, syndactyly, immune CACNA1C 12p13.3 Sporadic Few cases 
deficiency, hypoglycemia, cognitive abnormalities, autism  reported 
Tuberous Sclerosis 191100 Presence of hamartomata, epilepsy, learning difficulties,  TSC1 9p34.13 Autosomal dominant 1-4% 
  191092 behavioural problems, and skin and renal lesions. TSC2 16p13.3     
 605284     
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2.3.3 Cytogenetic findings 
The reported estimates of the rate of chromosomal aberrations have ranged from less 
than 5% to 48%, depending mainly on whether subjects with very low IQ or physical 
abnormalities are included. Chromosomal aberrations have been reported for most of the 
chromosomes, the most frequent findings being for the long arm of chromosome 15 and 
sex chromosomes (Gillberg 1998; Folstein and Rosen-Sheidley 2001).  
Chromosome 15q11-13 aberrations. Most of the reports of chromosomal abnormalities 
reported for chromosome 15 have been maternal duplications involving 15q11-q13 - 
region, which account for 1-3% of patients with autism (Gillberg 1998; Wassink et al. 
2001; Veenstra-VanderWeele and Cook 2004). Region 15q11-13 is a critical region for 
the Prader-Willi and Angelman syndromes, which are both associated with the autistic 
behavioural pattern (Steffenburg et al. 1996; Veltman et al. 2004). Other characteristic 
features for these syndromes have been listed in Table 3. Angelman syndrome results 
most commonly from a de novo maternal microdeletion of the chromosome 15q11-13, 
but a low frequency of Angelman syndrome cases is also caused by paternal uniparental 
disomy, UBE3A mutations, or imprinting mutations, in which the maternal chromosome 
has the paternal pattern of methylation (Veenstra-VanderWeele and Cook 2004). Prader-
Willi syndrome, by contrast, results from a de novo paternal microdeletion of the 15q11-
13 region or uniparental disomy for the maternal chromosome 15 (Veltman et al. 2004). 
It is probable that most of the structural abnormalities observed at 15q11-13 arise from 
recombinations involving highly homologous regions on both 15q11 (break-points BP1 
and BP2, see Figure 6) and 15q13 (BP3), which derive largely from duplications of a 
HERC2 (hect domain and RLD 2) gene (Nicholls and Knepper 2001). 
Consistently with the parental effect in the inheritance, the 15q11-13 region contains a 
cluster of genes which are subject to genomic imprinting. The promoter of the small 
nuclear ribonucleoprotein polypeptide N (SNRPN) gene is located within the CpG island 
that is completely methylated on the maternal chromosome and completely 
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unmethylated on the paternal chromosome. This region is denoted as the imprinting 
centre of the 15q11-13 locus (Shemer et al. 2000). The genes located proximally to the 
imprinting centre are paternally expressed, whereas the genes distally to imprinting 
centre are maternally expressed. A cluster of non-imprinted GABAA receptor genes is 
located further distally to the maternal expression domain, but yet within the autism 
critical region (Jiang et al. 1999). Angelman syndrome is thought to result from the lack 
of expression of the maternally expressed UBE3A gene in the brain, whereas other 
deleted genes are considered as having a modifying effect. UBE3A encodes a ubiquitin 
protein ligase, E6-AP, which is involved in the proteasome-mediated protein degradation 
(Jiang et al. 1999; Nicholls and Knepper 2001). The PWS critical region includes several 
paternally expressed genes but no single gene mutations causing PWS or a PWS-like 
disorder have been reported. Thus, there is no single gene, which would be 
unequivocally linked to the PSW phenotype (Nicholls and Knepper 2001). An overview 
of the genomic organization of the 15q11-13 locus is shown in Figure 6. Analyses of the 
15q11-13 candidates in autism have been reviewed in 2.3.5. 
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Figure 6. Critical region for autism, Angelman syndrome and Prader-Willi 
syndrome on 15q11-13. Abbreviations are as follows: BP, break-point; IC, imprinting 
center; MKRN3, makorin ring finger protein 3; MAGEL2, MAGE-like 2; NDN, Necdin; 
C15orf2, chromosome 15 open reading frame 2; SNRPN, small nuclear 
ribonucleoprotein polypeptide N; SNURF, SNRPN upstream reading frame protein; 
UBE3A, ubiquitin protein ligase E3A isoform 3; ATP10A, ATPase Class V type 10A; 
GABRB3, γ-aminobutyric acid (GABA) A receptor beta; GABRA5, GABA A receptor 
alpha; GABRG3, GABA A receptor gamma; OCA2, oculocutaneous albinism II; 
HERC2, hect domain and RLD 2. See text for further details. The figure is modified 
from Veenstra-VanderWeele and Cook (2004) and Nicholls and Knepper (2001) with 
additional data from the UCSC Human Genome Browser (May 2004 assembly).  
Turner syndrome. Another chromosome of frequent aberrations in autism is 
chromosome X, where a wide range of different abnormalities has been observed 
(Gillberg 1998). An interesting observation was made in girls with Turner syndrome, 
which affects females who possess only one copy of the X-chromosome. Skuse (2000) 
has reported that 6.4% of the girls with Turner syndrome who had inherited complete 
maternal X-chromosome developed autism. By contrast, none of the girls with Turner 
syndrome and paternally inherited X-chromosome had autism in a total sample of 221 
Turner girls. The girls with Turner syndrome who had inherited paternal X-
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chromosomes also did significantly better in a test of social-communicative skills than 
Turner girls with maternally inherited X-chromosomes. Similarly, in the general 
population girls have superior social-communicative skills compared to boys. Based on 
these observations, an imprinted-X liability threshold model for autism was proposed. 
According to this model, genetic vulnerability to autism is due primarily to the effects of 
the autosomal loci. Females with a normal karyotype have an imprinted protective locus 
that is expressed from a paternally inherited X-chromosome, and therefore females have 
a higher threshold for the expression of autistic features. The X-chromosome in males is 
maternally inherited and, consequently, males lack the protective effect. According to 
this model, the lack of a paternal X-chromosome would also predispose to poor social-
communicative - skills in general (Skuse et al. 1997; Skuse 2000).   
Balanced translocations. The chromosomal breakpoints caused by balanced 
translocations may provide a short cut to susceptibility gene identification, as 
exemplified by the cases of DISC1/DISC2 (disrupted in schizophrenia 1 and 2) in 
schizophrenia, FOXP2 (forkhead box P2) in developmental verbal dyspraxia, and 
DYX1C1 (dyslexia susceptibility 1 candidate 1; also known as EKN1) in dyslexia (Lai et 
al. 2000; Millar et al. 2000; Lai et al. 2001; Taipale et al. 2003). There have also been 
some attempts to identify candidate genes by such an approach in autism.   
The long arm of chromosome 7 has been a subject of intense research in autism because 
of overlapping linkage findings from several genome-wide scans (see, 2.3.4). An autistic 
individual carrying a translocation between chromosomes 7 and 13, t(7;13)(q31.3;q21), 
was found in a study by Vincent and colleagues (2000). A novel gene denoted as RAY1
(later known as suppression of tumorigenicity 7, ST7) was found to be interrupted by the 
translocational breakpoint, but the analysis of 27 unrelated autistic individuals failed to 
show phenotype-specific variants of this gene. Sultana and colleagues (2002) 
characterized a novel gene (AUTS2) located at 7q11.2, which was disrupted by a 
translocation in MZ twins with autism. No evidence for autism specific mutations or 
association was observed in a subsequent analysis of 65 families with autism (Sultana et 
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al. 2002). Also several other translocations for the 7q region have been reported in the 
autistic patients (Ashley-Koch et al. 1999; Warburton et al. 2000; Tentler et al. 2001).  
The Neurobeachin (NBEA) gene was found to be disrupted in an autistic patient with a 
de novo translocation t(5;13)(q12.1;q13.2) (Castermans et al. 2003). There are also three 
additional autism cases reported to carry a chromosomal abnormality involving the 
NBEA locus on 13q13.3 (Ritvo et al. 1988; Steele et al. 2001; Smith et al. 2002). One of 
the autism genome-wide scans has identified the NBEA locus as a potential susceptibility 
locus for autism (Barrett et al. 1999).  
A balanced t(X;8)(p22.13;q22.1) translocation has been reported to disrupt the gastrin-
releasing peptide receptor (GRPR) located at Xp22.13 in a female patient with autism 
(Ishikawa-Brush et al. 1997). Subsequently, Thomas and colleagues (1999) reported 
three females with Xp deletions involving the GRPR locus. It is of interest that the 
NLGN4 gene is located at Xp22.13 in the vicinity of the breakpoint reported by 
Ishikawa-Brush et al. (1997) and within the deleted region reported by Thomas et al. 
(1999).  
Finally, an apparently balanced t(2;8)(q35;q21.2) translocation, which involved partial 
deletion of the paired box 3 (PAX3) gene at 2q25 and a breakpoint at the matrix 
metalloproteinase (MMP16) gene at 8q21.2, has been reported in a boy with 
developmental delay and autism (Borg et al. 2002).  
2.3.4 Genome-wide scans and other linkage studies 
So far, a total of 10 genome-wide scans have been published in ASDs (IMGSAC 1998; 
Barrett et al. 1999; Philippe et al. 1999; Risch et al. 1999; Buxbaum et al. 2001; 
IMGSAC 2001b; Liu et al. 2001; Shao et al. 2002b; Yonan et al. 2003; Cantor et al. 
2005). In addition, two genome-wide scans have been performed in the Finnish 
population, as described in the experimental part of this thesis (studies I and II). Most of 
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the studies have included not only the strict phenotypic criteria for autism, but also 
broader autism phenotype involving individuals with AS and other PDDs. Also, several 
analyses focusing on specific chromosomal regions have been published (Ashley-Koch 
et al. 1999; Bass et al. 2000). Furthermore, there have been efforts to dissect the autism 
samples to dichotomous sub-groups, such as phrase speech delay (PSD) and obsessive-
compulsive behaviours, or to analyse quantitative traits associated with autism (Bradford 
et al. 2001; Buxbaum et al. 2001; Alarcon et al. 2002; Shao et al. 2002a; Buxbaum et al. 
2004; Alarcon et al. 2005). It is also of interest that overlapping sample is used in (i) the 
three studies by the International Molecular Genetic Study of Autism Consortium 
(IMGSAC) (IMGSAC 1998; IMGSAC 2001a; IMGSAC 2001b), (ii) the studies by 
Barrett and colleagues (1999) and Bradford and colleagues (2001), (iii) the three studies 
by Shao and colleagues (2002a; 2002b; 2003), and (iv) the studies, which have used the 
sample provided by the Autism Genetic Resource Exchange (AGRE) (Buxbaum et al. 
2001; Liu et al. 2001; Alarcon et al. 2002; Yonan et al. 2003; Buxbaum et al. 2004; 
Alarcon et al. 2005; Cantor et al. 2005). Thus, linkage evidence from these studies 
should not be considered as independent. The sample sizes have ranged from 51 families 
and 100 affected individuals in the study by the Paris Autism Research International 
Sibpair Study (Philippe et al. 1999) to 345 families with 732 affected individuals in a 
study by Yonan and colleagues (2003). Study samples have consisted mostly of 
Caucasian families, but commonly a small proportion of families with different ethnic 
origin has also been included. Generally, non-parametric linkage methods, especially 
sib-pair methods, have been favoured. The published linkage studies in autism have been 
listed in Table 4. The most promising findings have been summarized in brief below. 
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Table 4. Full-genome scans in autism. The three best loci from each scan are presented (given that MLS > 1.5). See text for 
further details.  
Study Sample size Ethnicity Phenotypes Best loci Maximum  Statistics 
          LOD score 
IMGSAC 1998 87 ASP 100% Caucasian autism, AS, PDD 7q32-34 2.53 ASPEX 
    4p16 1.55 Genehunter 
    16p13 1.51  
Barrett et al. 1999 75 ASP 95% Caucasian autism 13q22 3.0 ASP/MLINK 
13q12 2.3 
7q21 2.2 
Philippe et al. 1999 51 ASP 100% Caucasian autism 6q13 2.23 MAPMAKER/SIBS 
Risch et al. 1999 139 families 88% Caucasian autism 1p13.2 2.15 ASPEX
Buxbaum et al. 2001 95 families not stated autism, borderline  2p32 2.39 Genehunter NPL/HLOD 
   autism, AS 9q34 1.72  
IMGSAC 2001a/ 152 ASP 97% Caucasian autism, AS, PDD-NOS 2q13 3.74 ASPEX
IMGSAC 2001b (of which 83 analyzed atypical autism 7q22 3.2 
in IMGSAC 1998) 16p13 2.93 
17q11 2.34 
Liu et al. 2001 110 families mixed USA autism, AS; PDD Xq25 2.67 MAPMAKER/SIBS 
    5p13 2.55  
    19p13 2.53  
Shao et al. 2002 99 families 79% Caucasian autism Xq21 2.54 ASPEX
3p25 2.02 Parametric MLOD 
7q34 1.66 
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Table 4 continued       
       
Study Sample size Ethnicity Phenotypes Best loci Maximum  Statistics 
          LOD score 
       
Yonan et al. 2003 345 families mixed USA autism, NQA, PDD 17q11 2.83 MAPMAKER/SIBS 
    5p13 2.54  
    11p11-13 2.24  
Cantor et al. 2005 109 ASP mixed USA autism, NQA, PDD 17q21 1.90 MAPMAKER/SIBS 
3p13 1.80  
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Chromosome 2. In the follow-up study of their original genome-wide scan, IMGSAC 
reported the highest non-parametric multipoint MLS of 4.80 at 2q31 with the strict 
diagnostic criteria for autism (IMGSAC 1998; IMGSAC 2001b). The best linkage 
evidence in the study by Buxbaum and colleagues (2001) was reported for 2q32, only 
some 5 cM distally to the finding by IMGSAC. The highest non-parametric MLS was 
2.39 (Buxbaum et al. 2001). Also, Shao and colleagues (2002b) have reported modest 
linkage evidence for the long arm of chromosome 2. 
Chromosome 5. Liu and colleagues (2001) reported their best locus at 5p13 with MLS of 
2.55 in the initial analyses of the AGRE families. This region remained among the best 
loci in the follow-up study of the increased sample of 345 families with MLS 2.55 
(Yonan et al. 2003). Also, Buxbaum and colleagues (2001) have reported modest linkage 
evidence in the vicinity (5p15) with MLS 1.65, but it should be borne in mind that 
AGRE families were also included in this study. 
Chromosome 7. Linkage for the long arm of chromosome 7 was initially reported by 
IMGSAC (IMGSAC 1998) in 87 autism families with a multipoint MLS 2.53 at 7q32-
7q34. Their follow-up analysis with a total of 170 multiplex families resulted in the 
highest multipoint MLS of 3.37 at 7q22, some 25 cM proximally to the original finding 
(IMGSAC 2001a). In addition, the studies by Barrett and colleagues (1999) (MLS = 
2.2), Buxbaum and colleagues (2001) (MLS = 1.53), and Shao and colleagues (2002b) 
(MLS = 1.38) have reported modest evidence for linkage within the 7q21-34 region, 
which is currently denoted as autism susceptibility locus 1 (AUTS1).  
Chromosome 17. The best locus in the analysis of the AGRE sample was observed at 
17q11 with an MLS of 2.83 (Yonan et al. 2003). It was later suggested that this result 
was mainly due to increased sharing in male ASPs (Stone et al. 2004). This finding was 
later replicated in a subsequently collected sample of 91 AGRE families (Cantor et al. 
2005). Interestingly, also the second largest family material by IMGSAC provided 
suggestive linkage evidence for this region with an MLS of 2.34 (IMGSAC 2001b). The 
65
best marker in the IMGSAC study was intragenic for the serotonin transporter gene 
SLC6A4, which is considered as a strong functional candidate for autism (see, 2.3.5).  
Chromosome X. Both family and cytogenetic studies indicate that the X-chromosome 
might be involved in the aetiology of autism. Surprisingly, there are only two studies, 
which have reported linkage for chromosome X. Liu and colleagues (2001) reported an 
MLS of 2.56 at Xq25 (Liu et al. 2001). However, decreased linkage evidence (MLS < 2) 
for this locus was reported in a follow-up study (Yonan et al. 2003). Shao and colleagues 
(2002b) reported an MLS of 2.52 at Xq21, which is located 20 cM proximally to the 
peak by Liu and colleagues. 
Other chromosomes. Many of the loci that were among the best loci in independent 
studies have not been replicated by analyses of different samples. Risch and colleagues 
(1999) reported the highest LOD score in their sample for chromosome 1p13 with MLS 
of 2.15. This was the only locus that exceeded the MLS of 1.5 in their study (Risch et al. 
1999). The best autosomal locus in the genome-wide scan by Shao and colleagues 
(2002b) was observed at 3p25 with MLS of 2.02. The best locus in the genome-wide 
scan by Philippe and colleagues (1999) was observed at 6q16 with MLS of 2.23. Barrett 
and colleagues (1999) found the highest MLS of 3.0 at 13q22. They also reported a 
second peak on chromosome 13 (13q12) with MLS 2.3 at 13q12 (Barrett et al. 1999). 
Finally, the third highest peak in the IMGSAC sample was observed at 16p13 with MLS 
of 2.92 (IMGSAC 2001b). Also the first analysis of AGRE sample supported this 
finding, but only marginal evidence for linkage was observed in the follow-up analysis 
of 345 families (Liu et al. 2001; Yonan et al. 2003).  
Subgroup analyses. Re-analyses of the genome scan data have been performed by 
dividing the samples into component phenotypes in attempts to improve sample 
homogeneity. Although potentially helpful, the main disadvantage of this approach is 
that subgroup division necessarily compromises the sample size and thus the overall 
power to detect susceptibility loci. The primary sub-grouping considered to date has 
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been phrase speech delay (PSD) past 36 months, which occurs in about 50% of autistic 
disorder sibling pairs (Veenstra-VanderWeele and Cook 2004). Bradford and colleagues 
(2001) considered families with PSD (nfamilies=50) from the genome scan sample 
originally reported by Barrett and colleagues (1999). They showed that the linkage 
evidence obtained for the 7q21 and 13q22 were mainly attributable to the PSD group 
(Bradford et al. 2001). Buxbaum and colleagues (2001) incorporated analyses of PSD 
subgroup (nfamilies=49) in their genome-wide scan and observed increased linkage 
evidence at 2q32 with an NPL score of 3.32. Also Shao and colleagues (2002a) found 
increased evidence for linkage at 2q33 when the analyses were restricted only to families 
with PSD (nfamilies=45). The highest multipoint LOD score of 2.86 was observed some 20 
cM distally to the best marker in a study by Buxbaum and colleagues. Buxbaum et al. 
(2004) also analyzed a subset of autism families having obsessive-compulsive 
behaviours (nfamilies=62). They reported the best linkage evidence at 1q42 with an NPL 
score of 3.06, along with other putative loci at 6q14 and 19p13. Some of the regional 
subgroup analyses have provided increased linkage evidence for the 15q11-13 locus. 
Shao et al. (2003) showed that the LOD scores increased from 1.45 to 4.71 at the 
GABRB3 locus, when analyses were restricted to a subset of 23 families with high scores 
in the insistence of sameness factor. Nurmi and colleagues (2003b), by contrast, showed 
increased LOD scores for this region when a subgroup of 21 families with savant skills 
was analyzed. 
QTL analyses. Alarcon and colleagues (2002) used 152 families from the AGRE sample 
(Geschwind et al. 2001) and considered three quantitative measures from the Autism 
Diagnostic Interview – Revised (ADI-R) screening questionnaire (Lord et al. 1994): age 
at first word, age at first phrase, and repetitive and stereotyped behaviour. The best 
linkage evidence was observed at 7q34-36 when age at first word was used as the 
quantitative trait (p=0.002). This locus is located somewhat (3-38 cM) distally to the best 
markers of the AUTS1 locus reported in the IMGSAC sample (IMGSAC 1998; 
IMGSAC 2001a). Some evidence for repetitive and stereotyped behaviour was also 
observed at the same region (p=0.007) (Alarcon et al. 2002). In an expanded sample of a 
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total of 291 families, Alarcon and colleagues (2005) reported the highest peaks for age at 
first word for 3q (p<0.001) and 17q (p=0.002). 
Summary of linkage analyses. It is clear from the review above that there is no consistent 
linkage evidence across the studies for any chromosomal region. Another striking 
observation is that only one study reported LOD scores exceeding the proposed 
threshold for significant linkage regardless of the fact that the aetiology of autism is 
thought to have a remarkably strong genetic influence (IMGSAC 2001b). Such 
observations are thought to reflect truly extensive genetic heterogeneity of the disorder, 
but also methodological differences between the studies. It is encouraging, however, that 
the two largest data sets provided evidence for linkage at 17q11-12, which might 
indicate that the reliability of the analyses increases when larger samples are employed 
(IMGSAC 2001b; Yonan et al. 2003; Cantor et al. 2005). Putative overlapping linkage 
findings have been reported also for 7q and 2q. However, even if some of the findings 
most probably reflect true genetic susceptibility factors for autism, it will be difficult to 
restrict the critical susceptibility locus, especially when obvious functional candidate 
genes for autism do not exist.  
2.3.5 Candidate genes 
The list of positional or hypothesis-driven candidates that have been analyzed in autism 
is exhausting. Commonly, both positive and negative associations have been reported, 
which is characteristic for all candidate gene studies in complex neuropsychiatric 
disorders. Some of the most commonly analyzed candidates or genes with promising 
findings have been reviewed as examples below.  
SLC6A4/5-HTT. 5-hydroxytryptamine transporter gene (5-HTT; solute carrier family 6 
(neurotransmitter transporter, serotonin) member 4, SLC6A4) is probably one of the most 
intensively studies candidates in neuropsychiatric diseases. The 5-HTT is a target of 
selective serotonin reuptake-inhibitor (SSRI) drugs that are effective in treating anxiety, 
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depression, obsessive-compulsive behaviours, and also autistic behaviour (Glatt and 
Freimer 2002; Hollander et al. 2003b). Increased platelet and whole-blood serotonin 
levels have been reported approximately in one third of autistic patients and it has been 
suggested that this increase might be genetically determined (e.g. Abramson et al. 1989; 
Leventhal et al. 1990; Piven et al. 1991; Leboyer et al. 1999). It has therefore been 
hypothesized that the aetiology of autism could also be connected to the serotonergic 
system.  
The SLC6A4 gene has two functional variants, insertion/deletion polymorphism in the 
promoter region (5-HTT gene-liked promoter region, 5-HTTLPR) and VNTR in the 
second intron, which have been primarily considered in the candidate gene analyses of 
neuropsychiatric diseases. Evidence for association between SLC6A4 and autism was 
initially proposed by Cook and colleagues (1997), who reported preferential 
transmission of a short variant of the 5-HTTLPR in a sample of 86 trios of mostly 
Caucasian origin. Two subsequent studies have reported preferential transmission of the 
short allele (Conroy et al. 2004; McCauley et al. 2004b), whereas two other studies have 
reported preferential transmission of the long allele instead of the short variant (Klauck 
et al. 1997; Yirmiya et al. 2001). Most of the studies, however, have failed to show an 
association between 5-HTT variants and autism (Maestrini et al. 1999; Zhong et al. 
1999; Persico et al. 2000; Tordjman et al. 2001; Betancur et al. 2002; Kim et al. 2002a; 
Persico et al. 2002; Coutinho et al. 2004; Mulder et al. 2005). Also, haplotype analyses 
have revealed contradictory results (Cook et al. 1997; Betancur et al. 2002; Kim et al. 
2002a; Conroy et al. 2004; McCauley et al. 2004b).  
Recently, several studies have tested if the SLC6A4 promoter polymorphisms are 
associated with the blood or platelet 5-HT levels in families with autism. Like in the 
other analyses concerning SLC6A4 variants and autism, the conclusions have ranged 
from modest or a lack of association to significant contribution of the SLC6A4 to the 5-
HT levels (Anderson et al. 2002; Betancur et al. 2002; Persico et al. 2002; Coutinho et 
al. 2004). Furthermore, some authors have tested whether 5-HTTLPR polymorphisms 
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could be associated with rigid-compulsive behaviours in individuals with ASDs but, 
again, with conflicting results (McCauley et al. 2004b; Mulder et al. 2005).  
The analyses of SLC6A4 variants in autism provide a typical example of candidate gene 
analyses in complex neuropsychiatric diseases, in which it is often difficult to interpret 
the results across the studies. The reported associations have generally been modest and, 
noteworthy, multiple-testing corrected p-values were reported in none of the studies. 
Furthermore, only few studies have considered more than two polymorphism or LD 
across the SLC6A4 gene (Kim et al. 2002a; Conroy et al. 2004). Finally, the sample sizes 
have generally been modest ranging from 35 (Yirmiya et al. 2001) to 134 (Persico et al. 
2002) families of mixed origin, indicating that most of the studies have been 
underpowered. It is therefore evident that there is a high probability for both type I and II 
errors (Ott 2004). Taken together, there is currently no convincing evidence that SLC6A4
variants could confer susceptibility to autism or have an effect on hyperserotonemia in 
families with autism. 
Candidate genes on 7q. Numerous candidate genes have been studied at 7q based on the 
recurrent linkage findings for this chromosome in autism. RELN gene is located at 
7q22.1 and it encodes a protein called reelin. Hypothesis about the involvement of reelin 
in the pathogenesis of autism have been based on the relevant cellular function, deficits 
of reelin protein in post-mortem brains of autistic subjects, and reeler mouse with 
deleted RELN gene showing similar structural brain abnormalities that has been 
observed in autistic subjects. In addition, RELN gene variants have shown putative 
association in several other neuropsychiatric diseases such as schizophrenia and bipolar 
disorder (Fatemi 2002; Fatemi 2004). So far, seven association studies have been 
performed to analyze the role of the RELN gene in autism. Most of the studies have 
focused on the polymorphic CGG repeat located at the 5’UTR region of RELN gene. 
Two of these studies have shown evidence for association (Persico et al. 2001; Skaar et 
al. 2004) at the CGG repeat, whereas the others (Krebs et al. 2002; Zhang et al. 2002; 
Bonora et al. 2003; Devlin et al. 2004; Li et al. 2004) have yielded negative results.  
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The FOXP2 gene located at 7q31 is mutated in a monogenic severe speech and language 
disorder (MIM 602081) (Fisher et al. 1998; Lai et al. 2000; Lai et al. 2001). The 
rationale to analyze FOXP2 in autism comes from its physical location at autism 
susceptibility locus and from the phenotypic overlap of developmental language disorder 
and autism (Folstein and Mankoski 2000). Although one report of nominally positive 
association exists (Gong et al. 2004), the sequence and association analyses have 
generally failed to support the involvement of this gene in the etiology of autism 
(Newbury et al. 2002; Wassink et al. 2002; Gauthier et al. 2003). 
A homeobox transcription factor Engrailed2 (En2) is located close to the telomeric end 
of chromosome 7 at 7q36.3. The mouse mutants of En2 have been reported to have 
similar cerebellar morphological abnormalities as autistic patients, and thus En2 has 
been analyzed as a candidate for autism. Recently, Gharani and colleagues (2004) 
reported a relatively strong association between the intronic SNPs of En2 and autism. An 
earlier study by Petit and colleagues (1995) reported the association of one En2 variant 
in a case-control study. On the other hand, Zhong and colleagues (2003) failed to 
demonstrate an association in their family-based association test.  
Candidate genes on 15q11-13. The chromosome 15q11-13 has been a focus of several 
candidate gene studies based on the frequent chromosomal aberrations in this region in 
the autistic patients (see, 2.3.3) and also due to existence of relevant functional 
candidates in this chromosomal region. There are also some studies, which have reported 
modest evidence for linkage on this region (Bass et al. 2000; Nurmi et al. 2003b; Shao et 
al. 2003), but generally 15q11-13 has not been among the best loci in the genome-wide 
scans.
The most widely studied candidates have been members of the γ-aminobutyric acid 
(GABAA) receptor gene cluster, which contains genes coding for the α5, β3 and γ3
receptor units. GABA is the main inhibitory neurotransmitter in the human brain, 
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binding and acting through a complex series of GABAA receptors. It is also of interest 
that the GABAergic system is involved in the development of epilepsy (Baulac et al. 
2001; Wallace et al. 2001), which is observed in 30% of autistic patients (Gillberg and 
Billstedt 2000). As noted earlier, the Angelman syndrome gene, UBE3A, is also located 
within this locus. Yet another maternally imprinted gene located at 15q11-13, ATP10C 
(ATPase, Class V, type 10A), has been studied in autism. 
Most of the studies at 15q11-13 have included the GABRB3 gene, for which both 
positive (Cook et al. 1998; Buxbaum et al. 2002; McCauley et al. 2004a) and negative 
(Maestrini et al. 1999; Salmon et al. 1999; Martin et al. 2000; Menold et al. 2001) 
association findings have been reported. Some studies have reported nominal association 
evidence at GABRG3 (Menold et al. 2001) or GABRA5 (McCauley et al. 2004a). 
However, all the reported associations for the components of the GABAA gene cluster 
have been modest. The association studies of the UBE3A and ATP10C loci have 
provided modest evidence for association in some studies (Nurmi et al. 2001; Nurmi et 
al. 2003a) but not in others (Kim et al. 2002b). Mutation analyses have failed to detect 
any pathogenic mutations in these genes (Veenstra-VanderWeele et al. 1999; Kim et al. 
2002b). 
Other relevant candidates. The best linkage evidence obtained in the French genome-
wide scan for autism was observed at marker D6S283, which is intragenic for the 
glutamate receptor 6 gene (GluR6/GRIK2)(Philippe et al. 1999). Glutamate is the 
principal excitatory neurotransmitter in the brain and it is directly involved in cognitive 
functions. Therefore, glutamate receptors are candidates for several neuropsychatric 
diseases. A follow-up study of the genome-scan revealed increased IBD sharing of 
maternal alleles at the GRIK2 locus. Furthermore, a TDT analysis resulted in promising 
association at two GRIK2 variants. These associations were more pronounced when 
maternal transmission to male autistic subjects was tested suggesting an imprinting 
effect. Also, haplotype analysis with the two SNPs revealed a relatively strong 
association (Jamain et al. 2002). Modest association for this gene has been observed also 
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in the Chinese autistic trios (Shuang et al. 2004). More recently, evidence for association 
at GRIN2A gene (Glutamate receptor, ionotrophic, NMDA 2A) located on 16p13 was 
reported in the IMGSAC sample of 239 families and a replication set of 91 trios (Barnby 
et al. 2005). 
Finally, Ramoz and colleagues (2004) performed mutation screening in the candidates at 
the 2q24-33 locus and identified two SNPs that showed relatively strong association 
with autism in a sample of 411 families. The identified SNPs are located within the 
SLC25A12 gene, which encodes the mitochondrial aspartate/glutamate carrier 
(AGC1)(Ramoz et al. 2004). However, there are currently no published replication 
studies attempting to estimate the significance of this finding in independent samples.  
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3. AIMS OF THE PRESENT STUDY 
This study aimed to dissect the genetic complexity of ASDs by following aims: 
1) To use genome-wide approach to localize genetic loci, which harbour 
susceptibility genes for autism spectrum disorders in a well-characterized set of 
Finnish families.  
2) To perform a genome-wide scan in the Finnish families with clinically well 
defined Asperger syndrome.  
3) To perform combined data analysis of the genome-wide scans performed in the 
US and Finnish samples of autism families. 
4) To analyse positional and hypothesis-driven candidate genes in Finnish families 
to assess their role in the genetic background of autism. 
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4. SUBJECTS AND METHODS 
4.1 Laboratory procedures and analysis methods 
Methods used in this study have been described in detail in the original articles (I-V) and 
listed in Table 5. 
Table 5. Methods used in the present study. 
Method Original publication 
Laboratory procedures 
    DNA extraction I, II, III, IV, V 
    Polymerase Chain Reaction (PCR) I, II, III, IV, V 
    Agarose gel electrophoresis III, IV 
    Sequencing III, IV 
    Electrophoresis, ABI377/ABI3730 I, II, III, IV, V 
    Allele-specific primer extension – based microarray IV 
    Sequenom MALDI-TOF mass spectrometry V 
Analysis programs 
    Genescan 3.1 I, II 
    Genotyper 2.0 I, II 
    Genemapper 3.0 III, IV 
    SNPSnapper IV 
    Pedcheck 1.1 I, II, III, IV, V 
    Sequencher 4.0.5  III, IV 
Statistical methods 
    Downfreq 2.1 I, II, III, V 
    MLINK/LINKAGE I, II, IV 
    Homog 3.35 I, II, IV 
    Analyze I, II, IV 
    Genehunter v.2.1_r3beta;v.1.3 I, II, III 
    Pseudomarker  III, IV 
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Table 5 continued. 
Method Original publication 
    Simwalk 2.81 I 
    HRR I
    TDT-LRT I
    Gamete-competition I 
    FBAT IV, V 
    Dislamb I
    Haploview IV
    Genepop3.3; 3.4 I, V 
    Mendel 4.0 I
4.2 Study subjects 
4.2.1 Finnish families with autism, AS and dysphasia (I, III, IV,V) 
The family material used in the studies I, III, IV, and V was collected mainly via 
Helsinki University Hospital, Jyväskylä Central Hospital, and Kuopio University 
Hospital. These families included individuals diagnosed as having autism, AS, or 
developmental dysphasia. The diagnostic procedure used in the recruiting centres 
follows a highly uniform scheme. Initially, patients have been referred from outpatient 
clinic to the child neurological department for a two-week observation period involving 
a multidisciplinary battery of structured observations and tests. This period involves 
extensive diagnostic examinations, including neurological examinations, assessment of 
developmental history as well as psychological and neuropsychological evaluations 
using e.g. the Wechsler Intelligence Scale for Children – Revised (WISC-R) and 
Developmental Neuropsychological Assessment (NEPSY). Evaluations by speech 
pathologists, occupational therapists, and physiotherapists were performed using 
structured methods appropriate for the age and the developmental level of the child. 
Other specialists were consulted whenever it was considered necessary. During the 
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observation period, Childhood Autism Rating Scale (CARS) and the Psychoeducational 
Profile Revised (PEP-R) screening instruments were used to monitor autistic behavior 
and developmental profile. Both parents and a team of two nurses performed the CARS 
evaluation independently. Magnetic resonance imaging, electroencephalogram, 
cytogenetic screening, and a laboratory test package for detecting several metabolic and 
other disorders were routinely performed for all the patients. Families with associative 
medical conditions, such as fragile X syndrome, chromosomal aberrations, 
neurocutaneous syndromes, and profound mental retardation, were excluded from the 
sample. Particular attention was paid to the classification of the patients with 
developmental dysphasia. Reassessment was performed by a specialist for all the 
individuals diagnosed as having dysphasia. A total of 11/15 of patients with dysphasia 
had receptive language disorder (F80.2), which is similar to the DSM-IV diagnosis for
mixed receptive-expressive language disorder. Three patients had the expressive type of 
dysphasia (F80.1) similar to the DSM-IV diagnosis for expressive language disorder. In 
one patient with dysphasia diagnosis, the specific diagnosis remained unspecified in the 
reassessment. 
A stable team consisting of professionals with long experience carried out the diagnostic 
procedure and a consensus opinion of this team was required for the autism diagnosis. 
Finally, the diagnosis was set by a child neurologist in charge according to ICD-10 
(World Health Organization 1993) and DSM-IV (American Psychiatric Association 
1994) so that the criteria for both systems were fulfilled.  
4.2.2 Finnish AS families (II) 
Diagnostic examinations in the AS sample used in study II consisted of detailed, 
structured interview, which was based on the ICD-10 (World Health Organization 1993) 
and DSM-IV (American Psychiatric Association 1994) criteria for Asperger syndrome. 
In some cases, the Autism Spectrum Screening Questionnaire (ASSQ) (Gillberg and 
Gillberg 1989; Ehlers and Gillberg 1993; Ehlers et al. 1999) and the Asperger Syndrome 
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Diagnostic Interview (ASDI) (Gillberg et al. 2001) was used to collect additional 
information. Neuropediatricians or research nurses with long experience of ASDs 
conducted all the interviews. All the interviews performed by a research nurse were 
further evaluated by a neuropediatrician. Structured interviews with one or several 
family members were used to collect reliable anamnestic information of adults included 
in the sample. The diagnostic interview also included questions on hypersensitivity to 
external stimuli, face recognition difficulties (prosopagnosia), motor clumsiness and 
sleeping and eating disorders, which are not diagnostic criteria but have been reported to 
be frequently present in individuals with AS (Nieminen-von Wendt 2004; Nieminen-von 
Wendt et al. 2005). 
4.2.3 Autism Genetic Resource Exchange (AGRE) families (IV) 
The Autism Genetic Resource Exchange (AGRE) is a large central repository of DNA 
samples for genetic studies of autism. Families are recruited through a variety of 
methods, including physician referral, Web site contact, and family meetings and 
seminars (Geschwind et al. 2001; Liu et al. 2001; Yonan et al. 2003). The diagnostic 
assessment in the AGRE sample is based on the Autism Diagnostic Interview-Revised 
(ADI-R) (Lord et al. 1994), which is based on the classifications of the ICD-10 (World 
Health Organization 1993) and DSM-IV (American Psychiatric Association 1994). To 
be scored as affected, individuals must meet criteria in all three content areas of the ADI-
R, including (i) quality of social interaction, (ii) repetitive, restricted and stereotyped 
interests and behaviour, and (iii) age at onset <3 years (Lord et al. 1994). AGRE family 
collection included three diagnostic classes based on the ADI-R questionnaire: 
Individuals that met the criteria for the ADI-R were considered to be in the “narrow” 
autism category, the “not quite autism” (NQA) category includes individuals who are no 
more than one point away from meeting criteria in all domains but do not meet age-at-
onset criteria, and, lastly, individuals who might be considered as having AS or 
pervasive developmental disorder-not otherwise specified (PDD-NOS) were included in 
the “spectrum” category.  
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4.2.4 Diagnostic classes and sample sizes 
Three liability classes were generated for the sample of ASDs. The first class (LC1) 
included individuals with strictly defined autism, the second class (LC2) had also 
individuals with AS, and the third class (LC3) included family members with dysphasia 
as affected (studies I, IV, V). In studies III, IV and V, only families with at least one 
individual fulfilling the criteria for LC1 were selected for the analyses, whereas in study 
I some families with only broader classification (LC2 and LC3) were also included. The 
association analyses performed in studies IV and V were performed in a sample of 100 
families with 122 affected individuals in LC1.  
In the AS sample (study II), the first liability class (LC1) included individuals fulfilling 
the strict criteria for AS according to ICD-10. Family members who had AS–like 
features but who failed to meet one of the required criteria for diagnosis were included 
as affected individuals in a broad phenotypic category (LC2).  
For study III, we generated three new liability classes. The first liability class (LC1) was 
restricted only to individuals with a diagnosis of narrow autism in both samples. In the 
second LC (LC2), also individuals with NQA from the AGRE sample were assigned as 
affected, and the third liability class (LC3) included a broad spectrum of autistic 
disorders from both samples. The individuals diagnosed as having AS (LC2 in study I) 
in the Finnish sample were included in the LC3. Description of sample sizes in different 
diagnostic classes is shown in Table 6. 
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Table 6. Description of families used in studies I-V. The numbers refer to the total 
sample. The number of families and affected individuals in the primary scans are shown 
in parentheses.  
        
Study  Liability Class Families Affected Individuals 
        
I 1 18 (12) 39 (27) 
 2 28 (18) 72 (41) 
 3 38 (19) 87 (47) 
    
II 1 17 (13) 72 (62) 
 2 17 (13) 82 (66) 
    
IIIa 1 (AGRE) 188 402 
 2 (AGRE) 218 468 
 3 (AGRE) 288 621 
    
 1 (Finnish) 18 38 
 2 (Finnish) 18 38 
 3 (Finnish) 26 55 
    
 1 (Combined) 206 438 
 2 (Combined) 236 504 
 3 (Combined) 314 676 
    
IVb 1 19 41 
 2 26 56 
 3 33 74 
    
IV, V (association 1 100 122 
          analyses)c       
a) For a detailed sample description of the first stage, see the study III. Note that one individual 
included in LC1 in study I was changed as unknown. 
b) Only families with at least one individual fulfilling the criteria for LC1 in the study I were included. 
One novel family with three individuals in LC1 was included. Furthermore, one individual included 
in LC1 and one in LC2 in the study I were changed as unknown. 
c) Association analyses in studies IV and V included the 33 families used in linkage analysis of the 
study IV and 67 additional families with single affected (LC1). Only individuals fulfilling criteria 
for LC1 were assigned as affected in the analyses resulting in a total number of 122 affected 
individuals in LC1.  
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5. RESULTS AND DISCUSSION
5.1 Genome-wide scan of ASDs in the Finnish population (I) 
5.1.1 Primary scan 
We first performed a genome-wide scan in 38 Finnish families to identify genetic 
susceptibility loci for ASDs. The primary scan involved a genome-wide scan of 369 
microsatellites in a sample of 19 families with a total of 47 affected individuals. In the 
linkage analyses, nine regions on chromosomes 1, 3p, 3q, 9, 12, 14, 17, 18, and 21 
yielded in Zmax rec > 1.0 with the strict diagnostic criteria (Table 7). These loci were 
selected for follow-up analyses in the second stage. In addition to loci identified using 
strict diagnostic classification (LC1), some evidence for chromosome Xq13 was 
observed by using the broadest diagnostic classification (LC3). The best evidence was 
observed at DXS7132 in both two-point (Zmax dom=1.89, LC3) and multipoint 
(NPLall=2.75, p=0.0027, LC3) analyses.  
5.1.2 Fine-mapping 
In the second stage, the nine selected chromosomal regions were analysed further by an 
additional set of 60 markers. A total of 19 additional families with autism, AS, or 
dysphasia were included in this stage. The best linkage evidence was observed for 3q25-
27. The highest two-point LOD score was observed at D3S3037 (Zmax dom=4.31, LC2) 
and the highest parametric multipoint LOD score of 4.81 (LC2, dominant model) was 
observed at the same marker. Some supporting evidence for this locus was obtained from 
haplotype and association analyses (see, study I). Several markers genotyped at 1p13-
1q23 yielded Zmax > 1.0. The best two-point LOD score was observed at D1S1675 (Zmax 
dom=2.63, LC2), whereas in the multipoint analysis the highest LOD score of 2.63 (LC1, 
dominant model) was observed near D1S1653 located some 13 cM distally to D1S1675. 
Analyses at other fine mapping loci resulted in highly suggestive LOD scores. In 
addition to findings on 1p13-q23 and 3q25-27, LOD scores > 1.5 were observed only at 
3p24, 14q12, and 17q25. 
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Table 7. The highest two-point LOD scores LC1 in the primary scan. The LOD 
scores are maximized over recombination fractions (θ) ranging from 0 to 0.5. The α-
value ranging from 0 to 1.0 indicates the proportion of linked families. 
       
Marker Position  Model Z
max  θ-value α-value
 (cM)      
       
D1S1675 149  Dom 1.11 0.00 1.00 
D3S3038 45  Dom 1.67 0.00 0.77 
D3S4009 137  Rec 1.60 0.00 0.59 
D3S3554 153  Dom 1.90 0.00 1.00 
D3S3053 182  Rec 1.10 0.04 0.65 
D3S2427 188  Dom 1.77 0.00 1.00 
D3S2418 216  Rec 1.40 0.12 1.00 
D9S158 162  Rec 1.62 0.00 0.64 
D12S2078 150  Dom 1.30 0.00 1.00 
D14S297 32  Dom 1.55 0.00 1.00 
D17S784 117  Rec 1.43 0.04 0.51 
D18S59 0  Rec 1.22 0.00 0.40 
D21S1440 36  Rec 1.29 0.00 0.44 
       
5.1.3 Discussion of autism genome-wide scan 
In study I, we identified a major susceptibility locus for ASDs on 3q25-27 with 
convincing linkage evidence. This finding was supported by putative haplotype sharing 
of two families known to be related and by modest association findings using family-
based tests (study I). Generally, the 3q25-27 region has not been among the most 
promising regions in the autism scans (see, 2.3.4), which suggests that different autism 
predisposing alleles may have enriched in the Finnish population due to founder effect, 
genetic drift and isolation (Peltonen et al. 1999). The second best locus was identified on 
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1p13-q23. In contrast to the 3q locus, some evidence for the nearby region has earlier 
been reported by Risch and colleagues (1999), and more recently by Bartlett and 
colleagues (2005). The main shortcomings of this study are the small sample size and 
large number of statistical tests. Although no permutation analyses were performed, it is 
clear that with the current sample size there is a high risk for type I and II errors. Despite 
these limitations, the solid linkage findings for 3q25-27 and 1p13-q23 provide excellent 
starting point for the follow-up studies.  
5.2 Genome-wide scan of AS (II) 
Most of the genome-wide scans in ASDs have focused on families, which are 
ascertained through a proband with childhood autism and other ASDs exist only in the 
probands’ siblings. In the sample of Finnish families with ASDs we identified a group of 
families with AS, which were distinguishable from the families used in study I. First, AS 
was present without other ASDs. Second, the risk in the proband’s relatives seemed to be 
much higher than the risk in the families ascertained through a proband with childhood 
autism. Finally, a seemingly dominant mode of inheritance of AS was detected. Thus, 
these 17 families were selected as a separate group for the second genome-wide scan in 
study II. The pedigree structures are shown in Figure 7.  
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Figure 7. Pedigree structures for the 17 families in the AS genome-wide scan (II).
Families 3, 7, 8, and 15 were included only in the second stage of the study. 
5.2.1 Primary scan 
A genome-wide scan using a total of 415 microsatellites was performed in 13 
multigenerational AS families. In the primary scan, we covered the loci at 1q21-23, 
2q31-32, 3q25-27, 6q16, 7q, 13q12-22, and 16p13 with increased marker density based 
on the linkage findings from the earlier autism genome-wide scans. The two-point LOD 
scores were calculated by using the two liability classes and both dominant and recessive 
models. A total of 13 markers exceeded two-point LOD score of 1.5 in the primary scan. 
The best two-point LOD score was observed at 1q23.3 with D1S484 (Zmax dom=3.17).
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Also, three other markers, D1S1653, D1S2705, and D1S1677, spanning 12 cM exceeded 
the two-point LOD score of 1.5 in this region. Other loci with LOD scores > 1.5 were 
identified at 3p24.1, 3q28, 4p15.1, 4q32.3, 6p25.1, 6q16.1-q16.3, 13q32.1, and 
18p11.32, as shown in Table 8. These loci were selected for additional analyses in the 
fine mapping stage.  
5.2.2 Fine mapping 
In the second stage, the best loci observed in the first stage were analysed by using the 
complete sample of 17 AS families. We added 22 new markers at these loci, the total 
number of markers being 54 with an average intermarker distance of 3.2 cM.  
Altogether, 8 out of 20 microsatellites spanning 19.7 cM at 1q21-23 resulted in the two-
point LOD score > 1.0, the best marker being D1S484 (Zmax dom=3.58, LC1). The highest 
multipoint NPLall score at this locus was 1.33 (p=0.044, LC1). Eight markers covering 31 
cM were analysed at 3p14-24. The best marker was D3S2432 (Zmax dom=2.50, LC1), but 
three other markers at this region also exceeded the LOD score of 1.0. The results from 
the multipoint analyses were consistent with the two-point results, the highest NPLall 
score being 3.32 (p=0.0029, LC1) at D3S2432. Two out of six markers genotyped at 
13q31-33 exceeded the two-point LOD score of 1.0 in the second stage (D13S793, Zmax 
dom=1.59, LC2; D13S1271, Zmax dom=1.16, LC1). Increased linkage evidence was 
observed in the multipoint analyses with the NPLall of 2.86 (p=0.0025, LC1). Generally 
decreased LOD scores were observed for all the other loci included in the second stage 
analyses. However, markers with LOD scores > 1.0 were identified at all the fine 
mapped loci excluding 6p25.1 and 18p11.32, as shown in Table 8. 
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Table 8. The highest two-point LOD scores from stages I and II of study II. The markers with Z
max
 > 1.5 are presented.
                  
Marker Position    Stage I   Stage II 
 (cM)  LC Model Zmax LC Model Zmax 
          
D1S2715 159  - - -  1 Dom 1.75 
D1S2721 161  - - -  1 Dom 2.88 
D1S1653 164  1 Dom 2.47  1 Dom 1.53 
D1S484 170  1 Dom 3.17  1 Dom 3.58 
D1S2705 171  1 Dom 1.85  2 Dom 1.97 
APOA2 171  - - -  1 Dom 2.75 
D1S1677 176  2 Dom 1.78  2 Dom 1.21 
D3S2432 58  1 Dom 1.84  1 Dom 2.50 
D3S3685 68  - - -  1 Dom 1.54 
D3S2398 209  1 Rec 1.72  1 Rec 1.42 
D4S2408 46  2 Rec 1.99  2 Rec 1.04 
D4S2368 168  1 Dom 2.23  1 Dom 2.82 
D6S1668 9  1 Rec 1.66  1 Rec 0.85 
D6S1056 103  2 Dom 1.66  2 Dom 1.19 
D6S1671 108  2 Dom 1.73  2 Dom 1.07 
D13S793 76  1 Dom 1.74  2 Dom 1.59 
D18S59 0  1 Rec 1.71  1 Rec 0.98 
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5.2.3 Discussion of the AS genome-wide scan 
The most solid linkage evidence in the AS sample was observed at 3p14-24. Some 
earlier evidence for the nearby region was also observed in study I, in which two-point 
LOD score of 1.72 was observed with broad diagnostic classification (LC3) at D3S3659. 
This marker is located some 10 cM distally to the best marker D3S2432 in the AS 
sample. In their genome-wide scan of autism, Shao and colleagues (2002b) observed 
two-point LOD score 2.02 at D3S3680, which is located 22 cM distally to D3S2432.  
The results at 1q21-23 are much more difficult to interpret. Some of the markers yielded 
promising results in the two-point analyses, but the multipoint evidence was not 
compelling. Multipoint analyses are sensitive to incorrect marker ordering or small 
number of genotyping errors. On the other hand, two-point analyses may fail to 
recognize all the recombinations due to missing genotype data, which may lead to false 
positive peaks at some individual markers. It is interesting, however, that this locus was 
among the best loci also in study I. This locus has also been the subject of intensive 
study in schizophrenia based on promising linkage findings (Brzustowicz et al. 2000; 
Gurling et al. 2001). In schizophrenia samples, some association evidence has been 
reported for RGS4 and CAPON genes, which are both located at 1q23.3 (Chowdari et al. 
2002; Brzustowicz et al. 2004).  
Yet another putative susceptibility locus for AS was observed at 13q31-33. This locus 
has been among the best loci in schizophrenia studies, as it has also been in studies of 
bipolar disorder (Blouin et al. 1998; Brzustowicz et al. 1999; Detera-Wadleigh et al. 
1999; Kelsoe et al. 2001; Badner and Gershon 2002). In the regional candidate gene 
analyses, the locus for the G72/G30 gene at 13q33.2 has been reported to be associated 
with both schizophrenia and bipolar disorder (Chumakov et al. 2002; Hattori et al. 2003). 
Some shared features for some schizophrenia spectrum disorders and AS exist and some 
association between bipolar disorder and AS have also been suggested (DeLong and 
Dwyer 1988; Gillberg and Billstedt 2000; Wolff 2000). In our AS sample, three 
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individuals had an overlapping diagnosis of schizophrenia and one individual had 
bipolar disorder. Many family studies have found increased risk of depression, bipolar 
disorder and schizophrenia spectrum disorders in the relatives of patients with AS 
(DeLong and Dwyer 1988; Ghaziuddin 2005). Furthermore, one large-scale 
epidemiological study reported that risk for ASDs was markedly increased in children 
with a parental history schizophrenia-like psychosis or affective disorder (Larsson et al. 
2005). It is therefore possible that some trait components with common genetic origin 
might be shared across different diagnostic groups. However, it is equally true that many 
studies have found only little overlap of ASDs and schizophrenia (Volkmar and Cohen 
1991; Gillberg & Billstedt 2000; Cederlund and Gillberg 2004). 
Taken together, the two genome-wide scans performed in studies I and II revealed a 
putative shared susceptibility locus at 1q21-23. Furthermore, in study I some linkage 
evidence emerged for the best locus in AS sample at 3p14-24. Similarly, some linkage 
evidence for the best locus at 3q25-27 in study I was observed also in the AS sample 
(Table 8). The shared loci with the linkage studies of other neuropsychiatric disorders at 
1q21-23 and 13q31-33 might suggest the possibility of shared aetiological factors, but 
extensive studies are needed either to prove or disapprove these hypotheses.  
5.3 Combined data analysis for autism loci (III) 
The credibility of a linkage signal must be confirmed by an independent replication. In 
study III, we aimed (i) to pool raw genotype data from the Autism Genetic Resource 
Exchange (AGRE) and Finnish autism samples (study I) to reveal potential susceptibility 
loci common for both study samples, (ii) to analyze the best loci obtained in the AGRE 
sample in the study sample ascertained from the Finnish population, and (iii) to analyze 
the best loci that emerged from the Finnish sample in the AGRE families. This study 
design has a potential to confirm evidence for earlier identified susceptibility loci, but it 
could also identify novel loci for which the genetic effect is too small to be detected in a 
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single study, as exemplified elsewhere (Cavanaugh 2001; Demenais et al. 2003; 
Pajukanta et al. 2003).  
5.3.1. Initial combined data analysis 
As the first stage, we combined raw genotype data from study I and from the study by 
Yonan and colleagues (Yonan et al. 2003). A total of 572 markers were included in the 
combined data set, of which 265 (46%) were common to both genome scans. Markers on 
nine loci (1p12-q25, 3p24-26, 4q21-31, 5p15-q12, 6q14-21, 7q33-36, 8q22-24, 17p12-
q21 and 19p13-q13) exceeded the NPLall score of 1.64 (p<0.05) in the initial combined 
data analysis as shown in Table 9. In three of these, 1p12-q25, 3p24-26, 6q14-21, both 
datasets contributed to the linkage, whereas at the other loci linkage evidence emerged 
mainly from one data set only. On chromosome 1q, we observed the highest NPLall score 
of 2.25 (p=0.012) close to D1S1677 (LC3). On chromosome 3p, the best linkage 
evidence in the combined sample was detected at D3S2403 with NPLall of 2.10 
(p=0.014, LC2). Finally, on 6q the overlapping linkage signals in the AGRE and Finnish 
samples produced increased linkage evidence at D6S1021 (NPLall = 2.47, p=0.0046, 
LC1).
89
Table 9. Results from combined data analysis. The multipoint NPLall scores > 1.64 (p<0.05) in the initial combined data analysis 
and the corresponding NPLall scores from separate data sets are presented. Results from the second stage are shown where available. 
Marker positions from pter (in cM) are from the Marshfield genetic map. 
                                
Combined AGRE Finnish
Locus LC Location  Marker NPL
all p-value Location  Marker NPLall p-value Location Marker NPLall p-value 
(stage)  (cM)     (cM)     (cM)    
                
1p12-q25(I) 3 176 D1S1677 2.25 0.012  176 D1S1677 1.66 0.048  169 D1S2771 2.27 0.013 
1p12-q25(II) 3 176 D1S1677 1.82 0.033  176 D1S1677 1.33 0.088  169 D1S2771 2.27 0.013 
3p24-26 (I) 2 29 D3S3691 2.10 0.014 29 D3S3691 1.79 0.032 37 D3S2403 1.72 0.018 
3p24-26 (II) 2 29 D3S3691 2.20 0.011 29 D3S3691 1.79 0.032 37 D3S2403 1.62 0.028 
4q21-31 (I) 3 107 D4S1591 2.53 0.005  107 D4S1591 2.67 0.003    NS  
5p15-q12 (I) 3 57 D5S1490 1.82 0.032 57 D5S1490 2.04 0.019 19 D5S807 2.09 0.02 
6q14-21 (I) 1 112 D6S1021 2.47 0.0046  101 D6S1056 2.04 0.017  112 D6S1021 1.51 0.038 
6q14-21 (II) 1 112 D6S1021 2.05 0.014  101 D6S1056 2.04 0.017  112 D6S1021 0.57 0.222 
7q33-36 (I) 2 165 D7S483 2.31 0.008 165 D7S483 2.33 0.008 NS
8q22-24 (I) 3 132 D8S1832 2.07 0.018  132 D8S1832 2.2o 0.012    NS  
17p12-q21 (I) 3 50 D17S1294 2.39 0.007 50 D17S1294 2.71 0.0028 62 D17S1299 0.32 0.369 
17p12-q21 (II) 3 50 D17S1294 2.38 0.0076 50 D17S1294 2.71 0.0028 62 D17S1299 0.54 0.287 
19p13-q13 (I) 1 42 D19S714 1.77 0.032  42 D19S714 1.78 0.033    NS  
                
90
5.3.2. Follow-up analyses on chromosomes 1, 3, 6 and 17 
In the follow-up stage, we analyzed additional markers on 1p12-q25, 3p24-26 and 6q14-
21, where overlapping linkage peaks were observed in the first stage. Complete samples 
from both data sets were included at these loci. After follow-up analyses, the most 
promising overlapping linkage signal was observed at 3p24-26 with NPLall of 2.20 
(p=0.011, LC2) at D3S3691 in the combined sample. The best NPLall scores for this 
locus in the separate analyses of Finnish and AGRE sample were 1.62 (p=0.028) at 
D3S2403 and 1.79 (p=0.032) at D3S3691, respectively. For the 1p12-q25 locus, slightly 
decreased linkage evidence was obtained in the second stage. In the combined sample, 
the best linkage evidence was observed at D1S1677 (NPLall = 1.82, p=0.033, LC3). The 
best findings in the individual samples were observed at D1S1677 (NPLall = 1.33, 
p=0.088) and D1S2771 (NPLall = 2.27, p=0.013) in the AGRE and Finnish samples, 
respectively. Analysing of the complete Finnish sample at 6q14-21 resulted in decreased 
linkage evidence compared to the initial stage (D6S1056, NPL
all=0.57, p=0.222, LC1).
Therefore, the highest NPL
all score of 2.05 (p=0.014) in the combined sample is mainly 
contributed by AGRE families.  
The best loci observed in the separate analyses of Finnish and AGRE samples were 
3q26-28 and 17p12-21, respectively. Therefore, we analyzed the 3q26-28 locus in the 
complete sample of AGRE families and the 17p12-q21 locus in the complete sample of 
Finnish families. At 3q25-27, the AGRE data set produced the highest linkage evidence 
at D3S1763 (NPL
all = 1.30, p=0.089, LC1). With this same diagnostic classification, the 
Finnish sample produced the highest NPL
all of 2.53 (p=0.0014) close to D3S3037, which 
is located around 14 cM distally to D3S1763. This suggests the potential overlap of the 
peaks identified in two samples. Using the narrow disease classification, the best linkage 
evidence in the combined sample was NPL
all of 1.88 (p=0.024) at D3S1763. In the 
current analysis, the strongest linkage evidence in the Finnish sample was observed at 
D3S3037 (NPL
all = 3.37, p=0.00059) using a broad classification.  
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Consistently with the first stage analysis, no support for linkage at 17p12-q21 locus 
emerged from the Finnish data set after analyzing the complete sample at this locus in 
the second stage (D17S1299, NPL
all = 0.54, p=0.287, LC3). The best linkage evidence in 
both AGRE and combined samples were observed at marker D17S1294 with NPL
all of 
2.71 (p=0.0028, LC3) and NPL
all of 2.38 (p=0.0076, LC3), respectively.  
5.3.3. Sequence analyses of the OXTR gene 
The most promising shared locus for the AGRE and Finnish families was observed on 
3p24-26, where both AGRE and Finnish samples contributed to the linkage (Figure 8). 
The 1-NPL-drop support interval on 3p24-26 extends around 14 cM (22-36 cM from 
ptel) corresponding approximately to 8.2 Mb of genomic sequence. A functional 
candidate for autism, oxytocin receptor gene (OXTR), is located only 29 kb distally to 
the best marker D3S3691. We analyzed the entire protein coding sequence and flanking 
splice sites of this gene in 22 probands with autism (10 from the Finnish sample, 12 from 
the AGRE sample) by direct sequencing. The probands were selected from the families 
that produced the highest LOD scores for D3S3691. A total of four sequence variants 
were identified, but none of these are obvious functional variants (Table 10). All variants 
excluding 712G>A are present also in healthy controls and are listed in public SNP 
databases (dbSNP). The 712G>A variant changes a hydrophobic alanine to hydrophilic 
threonine in the cytosolic side of the protein and it was inherited from the father to both 
affected siblings in the family. This amino acid is not located within known functional 
domains and it is not conserved between species suggesting that amino acid substitution 
at this position may not influence the functional properties of the receptor (Gimpl and 
Fahrenholz 2001). We also tested association with D3S3691 and the flanking markers 
D3S4545 and D3S2403 by using Pseudomarker, but found no evidence for association 
with either of the data sets (data not shown).  
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Table 10. The OXTR variants detected in 22 autistic probands.  
          
Variant Exon Nucleotide  Amino acid Frequency in  
 number change change 44 chromosomes 
        
     
1 exon 3 171C>T N57N 34 
     
2 exon 3 652G>A A218T 6 
     
3 exon 3 690C>T N230N 11 
     
4 exon 3 712G>A A238T 1 
          
5.3.4. Discussion of combined data analysis 
Study III was initiated to test, whether we could see shared linkage region(s) among 
Finnish and AGRE family collections. One of the main motivations was also the more 
detailed analyzes of earlier identified susceptibility loci in the independent study 
samples. We observed the most promising shared locus for the two samples on 3p24-26 
(Figure 8). Also, some other studies with ASDs have provided linkage evidence for the 
nearby region. Most notably, Shao and colleagues (2002b) reported the second best locus 
in their genome-wide scan at D3S3680, which is located 7 cM proximal to the best 
marker in the combined data analysis, and only 1 cM away from the best marker in the 
Finnish data set. The best locus in study II was observed at D3S2432, which is located 
some 29 cM proximal to the best marker in the combined sample and 21 cM proximal to 
the best marker in the Finnish sample. 
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Figure 8. Linkage findings for 3p in study III and in earlier studies. The linkage 
curves have been indicated as follows: thick solid line = combined sample, thin solid line 
= Finnish sample, and thin dashed line = AGRE sample.  
The 3p24-26 region contains the oxytocin receptor gene (OXTR), which is thought to be 
an excellent functional candidate for autism. In addition to its well-recognized role in a 
94
variety of reproductive-related functions, oxytocin appears to have a role as a 
neurotransmitter or neuromodulator in the brain. Animal models have provided 
convincing evidence for its involvement in the basis of social attachment (Ferguson et al. 
2000; Insel and Young 2001; Winslow and Insel 2002). In autism, reduced oxytocin 
plasma levels as well as deficits in oxytocin peptide processing have been proposed 
(Modahl et al. 1998; Green et al. 2001). There is also some evidence that infusion of 
synthetic oxytocin would ameliorate repetitive behaviors in adults with autistic 
symptoms (Hollander et al. 2003a).  
As a preliminary analysis of OXTR gene, we sequenced the entire protein coding 
sequence in a sample of 22 autistic probands, but no obvious functional variants were 
detected. However, a more detailed study involving a dense set of markers is clearly 
needed in future to define the complete haplotype structure of this locus, and to test the 
association of OXTR variants with autism.  
Only modest support for the earlier identified susceptibility loci on 1q21-23, 3q25-27 
(study I) or 17q12 (Yonan et al. 2003) was observed in the independent study samples. 
These results support further the hypothesis of the enrichment of different autism 
predisposing alleles in the Finnish population due to the founder effect, genetic drift and 
isolation. Similarly, identification of only suggestive linkage signals in the large sample 
of 314 families proves once again that autism is genetically a highly heterogeneous 
disorder. However, this study indicates that the 3p24-26 locus deserves more attention 
and highlights the OXTR as a target for comprehensive molecular genetic studies in 
future. 
5.4 Analysis of neuroligins as candidates for autism (IV) 
Neuroligin genes have an essential role in the synaptogenesis and mutations in some of 
these genes have been shown to be causative for ASDs or MR, as reviewed in 2.3.2. Two 
out of the five members of the neuroligin gene family, namely NLGN1 at 3q26 and 
NLGN3 at Xq13, are located within best linkage peaks observed in study I, and were 
95
therefore considered as primary candidates for autism in our sample. We also wanted to 
include NLGN4 (located at Xp22) and its Y-chromosomal homologue NLGN4Y (Yq11) 
to the analyses based on the reported truncating mutations.  
A total of 30 probands (nmale = 26;  nfemale = 4) were selected for the mutation analyses of 
the coding regions and the splice sites of NLGN1, NLGN3, NLGN4, and NLGN4Y genes. 
One proband from all the families, where affected individuals shared at least one 
haplotype IBD on Xq13 and/or 3q25-27, were selected for the analyses. In addition, two 
probands from the families producing positive LOD scores for 3q25-27 in the AS sample 
(study II) were included in the mutation analyses. A total of 27 individuals had a 
diagnosis of autism (LC1) and 3 individuals were diagnosed as having AS (LC2). We 
identified a total of six variants in the NLGN1: two silent coding sequence variants 
(K494K [1482G>A] and P818P [2454C>T]), three intronic variants, and one 5’ UTR 
variant. None of these seemed to affect protein structure or were predicted to affect 
splicing (GeneSplicer Web Interface, the Berkeley Drosophila Genome Project, and the 
NetGene2 Server). We could not establish any sequence variants in NLGN4 or NLGN4Y
and only one rare variant was present in NLGN3. This was a silent Y74Y (222C>T) 
mutation in the first protein coding exon that was present in one affected male. Two of 
the variants identified in NLGN1 were common (493-45A>G corresponds to rs3853390 
and 1482G>A corresponds to rs7646919 in the dbSNP) and these were included in the 
SNP genotyping stage. Taken together, no obvious functional mutations were present in 
any of the genes analyzed. The identified variants have been listed in Table 11. 
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Table 11. Sequence variants identified in the mutation analysis of the NLGN1,
NLGN3, NLGN4, and NLGN4Y genes. A total of 30 individuals (nmale = 26; nfemale = 4) 
with ASDs were included in the analyses.
       
Variant Gene Mutation Nucleotide Amino acid Exon/ Frequency in the 
  type change change Intron autism sample 
       
1 NLGN1 5'UTR -24C>T - exon 3 1 (1.7 %) 
2 NLGN1 intronic 492+67A>G - intron 3 1 (1.7 %) 
3 NLGN1 intronic 493-45A>G - intron 3 11 (18.3 %) 
4 NLGN1 silent 1482G>A K494K exon 8 7 (11.7 %) 
5 NLGN1 intronic 1771-45A>G - intron 8 1 (1.7 %) 
6 NLGN1 silent 2454C>T P818P exon 9 1 (1.7 %) 
       
7 NLGN3 silent 222C>T Y74Y exon 2 1 (2.9 %) 
              
Excluding the possibility of coding sequence mutations is not sufficient when candidate 
genes are evaluated in the complex diseases. Therefore, we employed a dense set of 
microsatellite and SNP markers to further dissect the role of NLGN1, NLGN3, and 
NLGN4 genes. We genotyped a total of 16 microsatellites and 20 SNPs as follows: 6 
microsatellites and 18 SNPs in NLGN1, 6 microsatellites and 2 SNPs in NLGN3, and 4 
microsatellites in NLGN4 (Figure 9). Intragenic and flanking microsatellites were 
selected from the Marshfield Medical Research Foundation map and UCSC Human 
Genome Browser (July 2003 assembly). Since no intragenic markers were available for 
the NLGN3 gene, we generated two novel markers entitled ms.NLGN3-3 and 
ms.NLGN3-4, which were identified by using the Baylor College of Medicine Sequence 
Launcher’s repeat masker algorithm (Smith et al. 1996). The UCSC Human Genome 
Browser, Celera Discovery System and dbSNP were used for selecting the SNPs for the 
analyses.
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We confirmed the presence of linkage at the NLGN1 and NLGN3 loci, the best markers 
being D3S2421 (Zmax=2.58, LC1, dominant model) and DXS7117 (Zmax=2.39, LC2, 
dominant model), respectively. Also several other marker at these loci resulted in LOD 
score > 1.5, and thus the linked chromosomal region extends to overlap with NLGN1 and 
NLGN3. By contrast, none of the four microsatellites analyzed at the NLGN4 locus 
resulted in a LOD score > 1.5 (Table 12). Multipoint analyses were not performed, 
because the presence of LD between markers may lead to inflated LOD scores in 
analyses, which assume linkage equilibrium (Schaid et al. 2004). In association analyses, 
four out of 36 markers tested showed a trend towards association in a sample of 100 
families including a total of 122 patients diagnosed as having autism (LC1). In NLGN1,
the best association was observed at rs1488545 (FBAT, p=0.002; PSEUDOMARKER, 
p=0.041, recessive model). Also a nearby marker rs1352416, which was in LD with 
rs1488545 (D’ = 1.0), showed some trend towards association (FBAT, p=0.004; 
PSEUDOMARKER, p=0.07). However, the microsatellite D3S1565 located only ~500 
bp from rs1488545 did not show any evidence for positive association. Similarly, the 
analysis of two-marker haplotype constructed from rs1488545 and rs1352416 revealed 
less evidence for association compared with the evidence obtained for rs1488545 alone 
(rs1488545-rs1352416, p=0.01). Two of the X-chromosomal markers resulted in a 
nominal association in the dominant PSEUDOMARKER analysis. These were 
DXS7132 (p = 0.014) located at the 5’ side of NLGN3 and DXS996 (p=0.031) located 
within NLGN4 (Table 12).  
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Table 12. The markers, which yielded best linkage or association evidence in 
NLGN1, NLGN3 and NLGN4. Markers with Z
max
> 1.5 or p<0.05 are shown. NS refers 
to Z
max
< 1.0 in linkage analysis and p>0.05 in association analysis. The abbreviations are 
as follows: Het = heterozygosity, LC = liability class, Dom = dominant model, Rec = 
recessive model. 
        
Marker Het Linkage Model (LC) FBAT Pseudomarker 
Zmax p-value p-value 
          
NLGN1:      
             D3S1556 0.80 2.00 Dom (2) NS NS 
rs635255 0.34 1.95 Rec (2) NS NS 
 rs3853390 0.26 1.4 Dom (1) NS 0.025 (Dom) 
 rs1352416 0.22 NS  0.004 NS 
 rs1488545 0.23 NS  0.002 0.041 (Rec) 
      hCV1196655 0.44 2.16 Rec (2) NS NS 
D3S2421 0.85 2.58 Dom (1) NS NS 
NLGN3:      
DXS7132 0.74 1.89 Dom (2) - 0.014 (Dom) 
       ms.NLGN3-3 0.58 1.71 Dom (2) - NS 
DXS7117 0.37 2.39 Dom (2) - NS 
DXS6800 0.68 1.74 Dom (2) - NS 
      
NLGN4:      
DXS996 0.80 NS  - 0.031 (Dom) 
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Figure 9. Schematic overview of NLGN1, NLGN3, and NLGN4 genes. Genomic 
structures of the genes, analyzed SNPs and microsatellites as well as the identified 
sequence variants are presented. The sequence variant numbers correspond to the 
numbers in Table 11.  
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We identified a total of five haplotype blocks in NLGN1 by using a solid spine of the LD 
method (D’ > 0.8) of the HaploView - program (Figure 10)(Barrett et al. 2005). Block 1 
involved four common haplotypes, Block 3 had two common haplotypes, and the 
remaining blocks three common haplotypes with a frequency > 5%. We tested haplotype 
association within these blocks but none of them yielded significant results (p>0.05). 
Data from 11 out of 18 SNPs analysed on NLGN1 locus existed on the HapMap 
webpage. The LD pattern in the HapMap data (CEPH samples) was highly similar to the 
LD structure in the current Finnish sample (data not shown). 
Figure 10. Haplotype block structure of the NLGN1 gene. Haplotype blocks are 
defined by using the solid spine of LD method using D’ of 0.8 as a threshold. D’ values 
are shown within the boxes.  
There are many reasons for the excitement aroused by the identification of neuroligin 
mutations by Jamain and colleagues (2003) and Laumonnier and colleagues (2004). 
First, these findings suggest that at least a small fraction of typical cases of autism might 
be caused by rare mutations with a major functional effect. Second, it is intriguing to 
notice that similar truncating NLGN4 mutations seem to result in a wide variety of 
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phenotypes ranging from autism to the milder AS and to MR without autistic features. 
Third, neuroligin mutations link the aetiology of autism with mechanisms participating 
in the synaptogenesis and show that components involved in the synaptogenesis and 
synaptic structures are excellent functional candidates for future molecular genetic 
studies of autism and related disorders.  Finally, functional analyses of the neuroligin 
pathway may eventually lead to better a understanding of the pathophysiology of ASDs. 
We could not establish any functional mutations in any of the four neuroligin genes 
analyzed in 30 probands selected from families showing linkage for Xq13 and/or 3q26 
loci. This implies that the coding sequence variants do not explain the linkage observed 
in our data set. Our findings are also consistent with the findings in other recent studies. 
Two other research groups have analyzed NLGN3 and NLGN4 in a total of 292 samples, 
but no causative mutations were identified (Gauthier et al. 2004; Vincent et al. 2004). In 
addition, one recent study reported rare missense variants in NLGN4 but the atiological 
significance of these variants is not confirmed (Yan et al. 2005). Similarly, the two 
mutations described in the original report were identified among the sample of 158 
autistic patients (Jamain et al. 2003). Thus, neuroligin mutations seem to be real but rare 
causes for autism. It is important to notice, however, that by the current study design we 
cannot exclude the existence of rare neuroligin mutations in some autism cases also in 
the Finnish population. 
Although we identified a modest association at some of the markers analyzed, it is 
probable that they only account for random statistical fluctuation. The best association 
evidence was obtained for rs1488545 located in the fourth intron of NLGN1 using the 
FBAT analysis program. However, none of the nearby markers or haplotype-based 
association analysis supported this finding. Also, the two X-chromosomal markers 
yielded only highly suggestive associations. It is not well established how p-values 
should be corrected for multiple testing when the tested markers are tightly correlated, 
but it is evident that none of the associations reported here would remain significant if 
such corrections were performed (Hennah et al. 2004). It is equally clear that more 
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stringent significance level criteria than the traditional p<0.05 are needed for convincing 
associations in the presence of multiple testing and low prior probability (Ott 2004). 
Taken together, our findings do not provide strong evidence for the involvement of any 
of these genes in the aetiology of autism in the Finnish sample. 
5.5 Analysis of DYX1C1 variants in the Finnish autism families (V) 
Developmental dyslexia (MIM 127700) is the most common childhood learning disorder 
characterized by an unexpected difficulty in learning to read and write despite adequate 
intelligence, motivation, and education (Shaywitz 1998). Recently, the DYX1C1 gene 
(dyslexia susceptibility 1 candidate 1) located at 15q21 has been identified as a putative 
candidate gene for dyslexia in a Finnish dyslexia sample (Taipale et al. 2003).  
It has been suggested that DYX1C1 variants might play a role in the broad spectrum of 
common childhood neuropsychiatric disorders involving learning and acquisition of 
specific competences (Grigorenko 2003). Autism is an extreme example of such a 
disorder, having e.g. severe impairment of speech and language development among its 
essential features. Therefore, we wanted to test whether the phenotype influenced by 
DYX1 locus extends to autism by analysing the allelic distribution of the DYX1C1 gene 
in a sample of 100 Finnish autism families with 122 affected family members. A total of 
four intragenic SNPs spanning ~68 kb of genomic sequence were analysed including –
3G>A located on the 5’UTR (exon 2), rs3743204 in the second intron, 572G>A (G191E) 
in exon 5, and 1249G>T (E417X) in exon 10. We calculated family-based association 
for each individual marker as well as for two-, three-, and four-marker haplotypes 
constructed from the genotypes of the adjacent markers. None of these tests yielded 
positive associations as shown in Table 13. We also calculated the frequency of a two-
marker haplotype of –3A/1249T shown to be positively associated with dyslexia. In the 
original report, 13% of cases with dyslexia were shown to carry this haplotype versus 
5% of the controls, yielding an odds ratio of 2.8 ([CI95%]=1.2-6.5) (Taipale et al. 2003). 
The –3A/1249T haplotype frequency in the autism cases was 3%, which was equal to the 
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frequency in the unaffected founder individuals. Consistently with the association data, 
we did not observe linkage evidence with the DYX1C1 intragenic SNPs or with the 
flanking microsatellites genotyped in the study I.  
Table 13. Results from the DYX1C1 association analyses. The analyses were 
performed by the FBAT program using the empirical variance option. Minor allele 
frequencies for each SNP are shown in parentheses.  
        
       Variant df χ2 p-value 
        
    
Single markers 
     –3G>A (0.04) - - - 
     rs3743204 (0.09) 1 0 1 
     572G>A (0.42) 1 0.696 0.404 
     1249G>T (0.07) 1 0.727 0.394 
    
2 marker haplotypes 
     –3G>A + rs3743204 2 4.455 0.108 
     rs3743204 + 572G>A 2 1.167 0.558 
     572G>A + 1249G>T 2 2.053 0.358 
    
3 marker haplotypes 
     –3G>A + rs3743204 + 572G>A 2 1.919 0.383 
     rs3743204 + 572G>A + 1249G>T 3 1.256 0.74 
    
4 marker haplotype 
     –3G>A + rs3743204 + 2 1.059 0.589 
     572G>A + 1249G>T    
        
Despite the initial excitement of the results concerning DYX1C1 as a dyslexia 
susceptibility gene, the replication attempts have generally been unsuccessful. After 
completing the present study, at least four replication studies have been published in 
dyslexia samples, which have failed to demonstrate significant association either with 
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dyslexia or with quantitative measures of the dyslexic phenotype (Scerri et al. 2004; 
Cope et al. 2005; Marino et al. 2005). Although some modest association has been 
reported, they have been for different SNPs or towards the opposite direction compared 
to original report (Scerri et al. 2004; Wigg et al. 2004). Population specific or diagnostic 
differences have been suggested to explain these differences (Marino et al. 2005), but it 
is also true that both the sample size and associations in the original study were quite 
modest (Taipale et al. 2003). Therefore, an association between DYX1C1 variants and 
dyslexia cannot be considered as confirmed. Furthermore, we could not detect any 
evidence for association in the Finnish autism sample.  
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6. CONCLUDING REMARKS AND FUTURE 
PROSPECTS
To be successful, a genetic study needs a substantial contribution from experts in several 
fields. The foundation of this study has been collecting and characterising of more than 
250 Finnish families with ASDs or related traits by a clinical team with a strong 
expertise of ASDs. Thus far, the clinical part of the study has involved the 
characterisation of the sample by using mainly conventional diagnostic nomenclatures of 
ICD-10 and DSM-IV. We are currently developing this area of research further towards 
more detailed phenotypic characterisation using novel screening instruments, which will 
enable more specific subgrouping and quantification of the phenotype. One obvious 
benefit of this study is that the sample is collected from the isolated population of 
Finland with the high quality national health care system and availability to monitor the 
health of children throughout the childhood years. This should provide the advantage of 
a relatively homogeneous genetic background and also ensure improved diagnostic 
homogeneity. A unique characteristic of the Finnish autism sample is surprisingly 
extensive relations among the families, which may prove an important feature in the 
future genetic mapping studies. Such founder effect has clearly provided an advantage of 
potentially increased IBD-sharing also in the studies presented here. 
Sib-pair methodology has been the predominant mapping strategy in the autism studies. 
In the present study, we used our unique position in Finland to ascertain extensive 
families and extracted genetic information from entire pedigrees by using parametric 
methods. This approach should provide reasonably good power in linkage analysis even 
when a limited number of families are available. This was important because focusing on 
a small target population necessarily compromises the sample size available for mapping 
studies. The power of this study design is highlighted especially in study II, where up to 
11 affected individuals per family were present.  
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Several putative susceptibility loci were identified in the present study. Studies I and II 
provide a solid starting point for the future fine-scale mapping studies, especially at the 
best loci 3q25-27 (study I) and 3p14-24 (study II). It is worth mentioning here, that some 
additional support for the best AS locus on 3p14-24 was recently observed in a 
subsequently collected sample of Finnish AS families (Rehnström et al. in press). 
Another promising finding was that studies I and II yielded some evidence for shared 
loci, especially on 1q21-23, but also on some other loci, such as on 3p. Support for the 
3p region was observed also in study III, in which both Finnish and US families 
contributed to linkage for this locus. Although the studies of positional candidates 
(NLGN1, NLGN3, and OXTR) in studies III and IV did not yield promising results, they 
have been essential steps towards detailed characterisation of the identified linkage 
regions. Similarly, exclusions of other candidates, NLGN4 and DYX1C1 (studies IV and 
V), were based on the novel findings in the field of neuropsychiatric genetics and 
deserved detailed scrutiny in our sample. It is obvious, however, that with the sample 
size available it was possible to locate only variants with relatively strong effects.  
Genetic research of autism has yielded only limited success in the past decade despite 
the continuing growth of interest and funding for autism research as well as 
technological and statistical advances in the field of human genetics. The lack of success 
reflects the enormous difficulty of the problem, which undoubtedly arises from truly 
heterogeneous background of the autism phenotype. The predominant hypothesis 
explaining the inheritance of autism is that numerous interacting genetic variants with 
subtle effects combined with contributions of some environmental risk factors result in 
the phenotype. This assumption is based on the evidence obtained from the twin and 
family studies, as reviewed in 2.3.1. Similarly, poor reproducibility in the numerous 
genome-wide scans performed so far is indicative of a genetically heterogeneous 
background of the disease (see, 2.3.4). It should be borne in mind, however, that some 
rare high-penetrance mutations or chromosomal aberrations are known to be causative 
for autism (reviewed in 2.3.2 and 2.3.3). Thus, the assumption of common predisposing 
genetic variants with subtle effect is not entirely correct.  
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Although technological advances and rapid accumulation of biological information 
provide excellent tools for disease gene mapping, all the efforts will presumably be 
wasted unless they are combined with intelligent research strategies. If a combination of 
common variants with minor effect truly predispose to autism, large-scale genome-wide 
association studies using large samples might prove useful. The mapping of rare 
mutations with a strong effect requires large pedigrees and extensive mutation screening 
of the positional candidates. Yet the alternative approach is to focus on population 
isolates or small sub-isolates, in which single causative variant is enriched in the affected 
individuals. Furthermore, characterisation and measurement of several trait components, 
clinical subtypes, or quantitative traits, will most likely result in biologically relevant 
phenotypes, which might be more readily mapped than the end-phenotype. It is also 
clear that the latest technological advantages, such as gene expression profiling, array-
based copy number analysis, and high-throughput genotyping technologies, should be 
fully exploited. Therefore, the strategies to map autism genes should not be based only 
on one predominant hypothesis or approach, but rather, we should accept our ignorance 
of the true underlying genetic background and a variety of mapping strategies using 
different types of samples and methods should be employed.  
Despite the difficulties experienced so far, it is certain that genetic studies will 
eventually be able to characterize factors important for developing autism. This 
information will pave the way towards identification of novel metabolic pathways 
underlying autism, and thus provide new insights into the aetiopathogenesis of this and 
related disorders. It is hoped that in more distant future, this type of research will 
eventually result in development of new diagnostic markers enabling earlier and more 
specific diagnosis, and provide new starting points for drug development. 
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